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The somatotropic axis is one of the major hormonal systems regulating growth, 
development, and metabolism.  Growth hormone (GH) can act directly on target 
tissues or indirectly by stimulating insulin-like growth factor (IGF-I) through the 
JAK2-Stat5 pathway.  The first objective of this dissertation was to test whether 
exogenous GH could stimulate growth, development, and insulin resistance in the 
absence of functional Stat5 proteins.  Wild type (WT) and Stat5 mutant (Stat5N) mice 
were treated with exogenous GH for 4 weeks.  Stat5N mice grew at a slower rate and 
had lower hepatic IGF-I expression and plasma IGF-I than WT animals.  GH 
stimulated growth in WT animals but had absolutely no effect in Stat5N mice.  GH 
increased hepatic IGF-I expression and plasma IGF-I in WT mice but failed to do so in 
Stat5N mice.  GH-stimulated IGF-I expression also occurred in the muscle and 
adipose of WT mice only.  GH-treated Stat5N mice were protected from GH-induced 
insulin resistance.  This protection was associated with lack of GH-stimulated 
expression of p85 mRNA in insulin sensitive tissues. 
GH plays a critical role in mammary development through its modulation of 
mammary production of IGF-I and IGF binding proteins (IGFBPs).  One component 
of the IGF system that has not been studied in mammary development is the acid 
labile subunit (ALS).  ALS is thought to function exclusively by forming ternary 
 complexes with IGF-I and IGFBP-3 or -5 to build a reservoir of circulating IGF-I.  
The second objective was to evaluate the role of ALS in mammary gland development 
using null ALS mice.  Null ALS mice had three specific mammary defects, namely 
delayed ductal elongation, impaired ductal branching in early pregnancy, and delayed 
involution following lactation.  In contrast, mammary development during late 
pregnancy and lactation appeared normal in null ALS mice.  ALS mRNA was 
detected in the mouse mammary gland, and levels of expression were comparable to 
liver during pregnancy, lactation, and involution.  Therefore, mammary defects seen in 
null ALS mice cannot be attributed solely to disruption of the circulating IGF system 
and could relate partly to local ALS expression.  
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The growth hormone and insulin-like growth factor (GH-IGF-I) system plays 
essential roles in postnatal growth, development, and metabolism.  For example, Lupu 
et al. (2001) estimated that GH and IGF-I alone account for 14% and 35% of postnatal 
growth, respectively whereas their overlapping actions account for 34% of postnatal 
growth.  The overlapping actions represent GH actions mediated via its stimulation of 
IGF-I synthesis.  GH stimulation of IGF-I synthesis occurs in extra-hepatic tissues 
such as muscle and in liver (Mathews et al. 1986; Murphy et al. 1987).  The IGF-I 
produced by extra-hepatic tissue remains near its cellular site of production and 
represents the autocrine/paracrine arm of the IGF-I system (Le Roith et al. 2001).  
These IGF-I molecules are usually bound to one of six IGF binding proteins (IGFBPs) 
(Jones & Clemmons 1995; Stewart & Rotwein 1996).  Liver-derived IGF-I, on the 
other hand, is secreted in plasma and corresponds to the endocrine arm of the IGF-I 
system.  Circulating IGF-I is bound in a 150 kDa ternary complex composed of one 
molecule each of IGF-I, IGFBP-3 or -5, and the acid labile subunit (ALS), a protein 
produced predominantly by the liver (Baxter 1988; Twigg & Baxter 1998).   
Effects of GH are mediated through the growth hormone receptor (GHR).  
Binding of GH to its receptor leads to activation of JAK2.  This is followed by JAK2 
dependent activation of various signaling cascades (Lanning & Carter-Su 2006).  The 
growth promoting effects of GH are mediated predominantly by the signal transducer 
activator of transcription (Stat) 5a and 5b proteins (Waters et al. 2006).  Genetic 
mouse models have been created in which each individual Stat5 gene is ablated (Liu et 
al. 1997; Udy et al. 1997).  These models show that Stat5a is absolutely required for 
proper mammary gland development during late pregnancy and lactation, but Stat5a 
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appears to play no role in regulation of growth (Liu et al. 1997).  On the other hand, 
Stat5b plays important roles in regulating sexually dimorphic growth rates and male 
specific hepatic gene expression (Udy et al. 1997).   So far, no studies have ever 
directly assessed whether growth effects of exogenous GH were also lost in Stat5 
deficient mice.  Chronic administration of GH has been used to evaluate the 
responsiveness of various GH/IGF-I mutant models to exogenous GH (Liu & LeRoith 
1999; Liu et al. 2000b; Fielder et al. 1996).  Therefore, the objective of the work 
described in Chapter 3 was to test whether exogenous GH could stimulate not only 
overall growth of Stat5N mice but also other GH-dependent responses such as organ 
growth and insulin resistance.  
As mentioned above, ALS is responsible for formation of ternary complexes 
and the development of the circulating IGF-I reservoir (Baxter 1988; Twigg & Baxter 
1998).  So far, ALS has been postulated to function exclusively as a component of the 
circulating IGF-I system.  Additional studies have established that IGF-I deficiency 
associated with lack of ALS has functional impacts.  First, null ALS mice suffer a 13-
20% growth deficit after birth (Ueki et al. 2000).  Bone length is shorter and bone 
metabolism is impaired in null ALS mice (Yakar et al. 2002).  Null ALS mice have 
normal plasma glucose and insulin concentrations (Ueki et al. 2000) but are protected 
from GH-mediated insulin resistance (Haluzik et al. 2003).  These studies demonstrate 
a functional role for ALS in postnatal growth and metabolism, but the role of ALS in 
mammary gland development has not been studied.   
The mammary gland undergoes extensive morphological and biochemical 
changes during postnatal life. These dynamic changes are under strict hormonal 
control by sex steroid hormones and various growth factors (Richert et al. 2000). GH, 
IGF-I, and IGFBPs are involved in mammary development.  A role for ALS, either 
through its ability to modulate plasma IGF-I or through local effects, has never been 
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considered.  Therefore, the objective of the work described in Chapter 4 was to 
evaluate the role of ALS in mammary gland development using the null ALS mouse 







The somatotropic axis is one of the major hormonal systems regulating growth, 
development, and metabolism (Le Roith et al. 2001).  Growth hormone (GH) can act 
directly on target tissues, or it can act indirectly by stimulating insulin-like growth 
factor (IGF-I) production in liver and extra-hepatic tissues.  Liver derived IGF-I is 
secreted in plasma and represents the endocrine arm of the IGF system whereas extra-
hepatic IGF-I production represents the autocrine/paracrine arm (Le Roith et al. 2001).  
In circulation and the extracellular space, IGF-I is bound to one of six insulin-like 
growth factor binding proteins (IGFBPs).  Before birth, IGF-I circulates in a binary 
complex in which IGFBP-2 is the predominant IGFBP (Jones & Clemmons 1995).  
Upon induction of acid labile subunit (ALS) synthesis after birth, circulating IGF-I is 
bound in a 150 kDa ternary complex composed of one molecule each of IGF-I, 
IGFBP-3 or –5, and ALS (Baxter 1988; Twigg & Baxter 1998).  A second IGF 
protein, IGF-II, exists but is not regulated by GH and plays no role in mediation of GH 
effects.  Therefore, IGF-II will not be discussed extensively in the following pages.     
In the first part of this review, the components of the IGF system will be 
described.  These include IGF-I and IGF-II, their receptors and binding proteins, and 
the ALS.  Growth hormone is the most important regulator of IGF-I and ALS 
expression, and its effects on the IGF-I system are mediated predominantly via the 
signal transducers and activators of transcription 5 (Stat5) proteins (Woelfle & 
Rotwein 2004).  Therefore, the second section will provide an overview of growth 
hormone receptor signaling with emphasis on Stat5 and the molecular mechanisms 
whereby Stat5 regulates IGF-I and ALS gene expression.  The final section covers the 
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functional role of the somatotropic axis in postnatal growth, carbohydrate metabolism, 
and mammary development.   
COMPONENTS OF THE IGF SYSTEM  
The insulin-like growth factors and their receptors 
IGF-I and IGF-II (IGFs) are insulin-like peptides of 70 and 67 amino acids, 
respectively (Humbel 1990; Daughaday & Rotwein 1989).  IGF-I and IGF-II are 
synthesized by many tissues and are regulated by many different factors.  IGF-II 
expression in the rodent is high during fetal life but in contrast to most other species, 
decreases to undetectable levels after birth (Stempien et al. 1986; Graham et al. 1986; 
Brown et al. 1986), resulting in virtually no circulating IGF-II in adult rodents (Moses 
et al. 1980).  IGF-I levels are reciprocal to IGF-II levels:  IGF-I levels are low during 
fetal life and increase after birth (Daughaday et al. 1982; Singh et al. 1991; Hwang et 
al. 2008).  In the adult mouse, the primary source of circulating IGF-I is the liver, 
accounting for approximately 75% of plasma IGF-I (Yakar et al. 1999; Sjogren et al. 
1999).   
Three types of receptors are recognized by the IGFs.  The IGF-I receptor (IGF-
IR) binds IGF-I with greatest affinity, followed by IGF-II and then insulin.  The IGF-
IR has 100-1000 fold higher affinity for IGF-I than insulin and a 2-15 fold higher 
affinity for IGF-I than IGF-II (Jones & Clemmons 1995).  The IGF-II receptor (IGF-
IIR) binds IGF-II with greater affinity than IGF-I and does not bind insulin.  The 
insulin receptor (IR) binds insulin with highest affinity, followed by IGF-II and then 
IGF-I (Humbel 1990).  The biological effects of IGFs are mediated through the IGF-
IR while the IGF-IIR removes excess IGF-II from circulation (O'Dell & Day 1998). 
The IGF-IR and insulin receptor are structurally related and share 50% amino 
acid sequence identity.  Both receptors are heterotetramers composed of two  and 
two  subunits linked by disulfide bonds.  The extracellular ligand-binding domain is 
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formed by the  subunits, and the transmembrane and intracellular domains are 
formed by the  subunits (Humbel 1990; Stewart & Rotwein 1996).  The intracellular 
domain contains a tyrosine kinase and sites of tyrosine phosphorylation necessary for 
signaling.  Two of the more important signaling cascades engaged by the activated 
IGF-IR are the mitogen-activated protein kinase (MAPK) pathway and 
phosphatidylinositol 3-kinase (PI3K) pathway via activation of insulin receptor 
substrate-1 (IRS-1) (Laviola et al. 2007).   
IGF binding proteins 
In circulation and the extracellular space, IGFs are bound to a family of 
structurally related binding proteins called IGF binding proteins (IGFBP).  Currently, 
six different IGFBPs (named IGFBP-1 to –6) have been identified.  The binding 
protein genes range in size from 5 kb to more than 30 kb, but all genes contain 4 
conserved exons (Firth & Baxter 2002).  The amino and carboxy terminal ends of 
these six proteins are conserved while the middle domains differ (Rechler 1993).  
Mutagenesis studies have demonstrated that the amino and carboxy terminal ends 
form a binding pocket for IGFs, and the middle region is responsible for the unique 
functions of the individual binding proteins (Clemmons 2001). These binding proteins 
have numerous functions that include, but are not limited to, extending the half-lives 
of IGFs, determining the bioavailability of IGFs, and modulating IGFs’ biological 
activities.  IGFBP-2, -3, and –5 are the primary IGFBPs that comprise the circulating 
IGF system.  For these reasons, the remainder of this section will focus on IGFBP-2, -
3, and –5. 
IGFBP-2 
The mouse IGFBP-2 gene encodes a 31 kDa protein that shares 97% homology 
with the rat IGFBP-2 protein (Kelley et al. 1996; Landwehr et al. 1993).  IGFBP-2 
contains an RGD sequence known to bind integrin-like receptors, but such a property 
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has yet to be described for this IGFBP (Wetterau et al. 1999).  IGFBP-2 has a higher 
affinity for IGF-II than IGF-I and is thought to be particularly effective at inhibiting 
IGF-II actions (Firth & Baxter 2002).   
Most of the circulating IGFs are bound to IGFBP-2 during fetal life and to 
IGFBP-3 during postnatal life. In the mouse, IGFBP-2 is detected at embryonic d10.5 
(E10.5).  Message levels in the liver increase significantly after birth, reach maximum 
levels at postnatal d3 (P3), and remain abundant thereafter (Schuller et al. 1994).  The 
IGFBP-2 message also is detected in the kidney, lung, brain, spleen, testis, and ovary 
(Schuller et al. 1994).  Developmental expression of hepatic IGFBP-2 differs in the rat 
such that it is high during fetal life but is barely detectable in adulthood (Margot et al. 
1989).    
IGFBP-3 
The IGFBP-3 gene encodes a 34 kDa protein.  Three glycosylation sites are 
present which produce circulating forms that range in size from 40 and 44 kDa 
(Rechler 1993).  In the mouse, IGFBP-3 is detected at E11.5 in the embryo and 
reaches maximum levels in the liver at P7 of postnatal age.  IGFBP-3 mRNA is also 
detected in kidney, lung, heart, spleen, and muscle (Schuller et al. 1994; Cerro et al. 
1993).  In the rat, IGFBP-3 mRNA is highest in the kidney but is also expressed in 
liver, stomach, placenta, and uterus (Albiston & Herington 1992).  In the liver, 
IGFBP-3 has been localized to the nonparenchymal cells and is not expressed in 
hepatocytes (Chin et al. 1994; Scharf et al. 1996). 
After birth, IGFBP-3 is the most abundant IGFBP in circulation with its 
concentration surpassing that of any other IGFBP by ~10-fold (Baxter 1994).  
Furthermore, IGFBP-3 has the highest binding affinity for IGF-I (Rechler 1993) such 




The IGFBP-5 gene encodes a 29 kDa protein.  Variation in glycosylation 
results in the appearance of IGFBP-5 as a triplet of 29-34 kDa when analyzed by 
Western ligand blot (James et al. 1993; Wetterau et al. 1999; Schneider et al. 2002).    
It is highly conserved across human, rat, and mouse (97%) (Kou et al. 1994).  IGFBP-
5 is detected in the E11.5 old mouse embryo (Schuller et al. 1994).  In the adult 
mouse, IGFBP-5 mRNA is detected at high levels in the kidney, uterus, and skeletal 
muscle and at lower levels in the lung, heart, and brain, but expression is completely 
absent in the liver (James et al. 1993; Shimasaki et al. 1991; Schuller et al. 1994) 
(Kou et al. 1994).   
The acid labile subunit and ternary complex formation 
ALS plays a crucial role in the circulating IGF system as it is responsible for 
formation of the ternary complex.  Purified human ALS migrates as a doublet with a 
molecular mass of 84-86 kDa by SDS-PAGE analysis.  N-glycanase treatment 
decreased the molecular mass to 60-64 kDa demonstrating that serum ALS is 
glycosylated (Baxter et al. 1989; Dai & Baxter 1992).   
In rat, baboon, sheep, and pig, ALS mRNA expression has only been detected 
in the liver by Northern analysis (Dai & Baxter 1994; Delhanty & Baxter 1996; 
Rhoads et al. 2000; Lee et al. 2001).  In contrast, ALS expression was detected in the 
liver, gonadal fat, and kidney of both male and female mice (Giesy 2004).   
 Expression of ALS is barely detectable by Northern analysis in the liver of rats 
between birth and P10 of age.  Expression is induced around P21 of age and reaches 
maximal levels by P42 (Dai & Baxter 1994).  In contrast to the rat, hepatic ALS 
mRNA was easily detected at P1 of age in the mouse (Giesy 2004).  By in situ 
hybridization, a more dramatic increase in hepatic ALS expression was observed 
between birth and P20 of age in the rat (Chin et al. 1994).  At one week of age, 
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circulating ALS concentrations are ~1000 ng/mL.  Levels increase 5-fold by 8 weeks 
of age and decline slightly with increasing age (Hwang et al. 2008).    
The ALS protein is most prevalent in plasma (Baxter & Dai 1994).  Based on 
the mRNA data described above, most of circulating ALS is thought to be synthesized 
by liver.  After birth, ALS recruits IGF-I into ternary complexes composed of one 
molecule each IGF-I, IGFBP-3 or –5, and ALS (Baxter 2000).  The prevalent ternary 
complex is one where the IGFBP moiety is IGFBP-3.  Appearance of ALS and 
formation of the ternary complex are thought to be important steps in the development 
of the endocrine IGF-I system.  ALS associates with the binary complex of IGF-I and 
IGFBP-3 or –5.  ALS binds only binary complexes as it has virtually no affinity for 
either IGF-I or IGFBP alone (Baxter et al. 1989).  ALS circulates in 2-3 molar excess 
over IGF-I and IGFBP-3, driving 75% of circulating IGF-I into ternary complexes 
(Baxter 1990).  Only 10% of IGFBP-3 is found in its free form in circulation (Baxter 
et al. 2002).  In humans, ~55% of circulating IGFBP-5 is bound to IGF-I and ALS 
(Twigg & Baxter 1998; Baxter et al. 2002).  These IGFBP-5 ternary complexes are 
not as abundant as IGFBP-3 complexes because circulating levels of IGFBP-5 are 
only 10% of IGFBP-3 levels (Baxter et al. 2002; Baxter 1988).    
Free IGF-I has a half-life of 10-12 minutes.   The half-life of IGF-I is extended 
to 20-30 minutes when in binary complexes and to 12-15 hours when in ternary 
complexes (Zapf et al. 1986; Guler et al. 1989).  The dramatic increase in IGF-I half-
life when in a ternary complex stems from the inability of ALS to cross the endothelial 
barrier (Binoux & Hossenlopp 1988). 
GROWTH HORMONE REGULATION OF THE IGF SYSTEM 
Effects of GH are mediated through the growth hormone receptor (GHR).  
Signaling is initiated when GH sequentially recruits two GHR monomers.  This 
dimerization event causes a conformational change, aligning two Janus kinase 2 
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(JAK2) molecules (Dominici et al. 2005).  These tyrosine kinases activate one another 
via transphosphorylation and phosphorylate tyrosine residues on the GHR. The 
phosphorylated residues on both molecules serve as docking sites for downstream 
signaling mediators (Lanning & Carter-Su 2006).  Upon JAK2 activation, GHR 
signaling can proceed through three main pathways:  signal transducers and activators 
of transcription (Stat) pathway, mitogen-activated protein kinase (MAPK) pathway, 
and phosphatidylinositol 3-kinase (PI3K) pathway.  More recently, GH has been 
shown to activate the tyrosine kinase Src independent of JAK2 activation (Lanning & 
Carter-Su 2006; Brooks et al. 2008).  Termination of JAK/Stat signaling in the GHR 
pathway is mediated by three families of proteins: the suppressors of cytokine 
signaling (SOCS), the SH2-containing phosphatases [SHP, also known as 
phosphotyrosine phosphatase (PTP)], and the protein inhibitors of activated Stats 
(PIAS) (Wormald & Hilton 2004).  A more detailed overview of the GH signaling 
pathway is given below.   
GH Signaling pathways 
 GH activation of the Stat proteins has been studied extensively (Herrington et 
al. 2000).  GH activates Stat5 predominantly and to a lesser extent, Stat1 and Stat3 
(Hosui & Hennighausen 2008).  Upon activation of JAK2, Stat proteins are recruited 
to phosphorylated tyrosine residues on the GHR via their SH2 domains, followed by 
JAK2 phosphorylation of specific tyrosine residues on Stat proteins.  The Stat proteins 
can then homo- or heterodimerize, translocate to the nucleus, bind specific DNA 
sequences, and activate transcription (Herrington et al. 2000).   
 To activate the MAPK pathway, Shc, an SH2 domain containing adapter 
protein, is recruited to the receptor and phosphorylated.  Phosphorylated Shc binds 
growth factor receptor binding protein-2 (Grb2) and the guanine nucleotide exchange 
factor, Son of Sevenless (SOS).  The assembly of this complex brings SOS in close 
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proximity to the membrane and enables activation of the small GTP-binding protein, 
Ras (Piwien-Pilipuk et al. 2002).  Ras then activates the serine/threonine kinase, Raf, 
which activates the tyrosine/serine/threonine kinase, MEK, and MEK specifically 
activates ERK1 and 2.  ERKs can phosphorylate many different proteins, including 
cytoskeletal targets, cytosolic proteins, and nuclear proteins (Carter-Su et al. 2000).  
The MAPK pathway has been implicated in GH-stimulation of c-fos, egr-1, and junB 
transcription (Piwien-Pilipuk et al. 2002). 
 The final pathway that I will describe is GH-activation of PI3K.  GH 
stimulates JAK2 phosphorylation of insulin receptor substrates (IRS) -1 and -2 which 
allows IRS proteins to interact with PI3K.  PI3K is composed of two subunits, the 
regulatory subunit p85 and the catalytic subunit p110.  IRS binds to p85 which 
relieves the basal inhibition of p110 and recruits the heterodimer to its substrate at the 
plasma membrane (Engelman et al. 2006).  Activation of PI3K converts lipid second 
messengers, phosphatidylinositol-3,4-bisphosphate (PIP2) to phosphatidylinositol-
3,4,5-triphosphate (PIP3) (Hirsch et al. 2007).  These lipid messengers bind to the 
pleckstrin homology (PH) domain of 3-phosphoinositide-dependent kinase-1 (PDK-1) 
and the serine/threonine kinase Akt (also known as protein kinase B).  Akt can activate 
various processes including stimulating glycogen synthesis, glycolysis, and cell 
survival via inhibition of pro-apoptotic factors (Piwien-Pilipuk et al. 2002) 
Inhibitors of GH signaling 
Several mechanisms limit GH signaling.  The SHP and PIAS proteins are 
constitutively expressed and attenuate GH signaling by dephosphorylating JAK2 and 
GHR and repressing Stat activity, respectively (Wormald & Hilton 2004).  The SOCS 
family of proteins is an inducible inhibitor of the GH pathway and can interfere 
directly with the signaling cascade and can target the receptor for proteasomal 
degradation (Wormald & Hilton 2004).   
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Three different phosphatases, SHP1, PTP1b, and PTP-H1 are involved in 
down regulation of GHR signaling.  GH activates SHP1, resulting in nuclear 
translocation.  In the nucleus, SHP-1 binds Stat5b and attenuates its activity.  SHP1 
also binds JAK2 and controls the duration of JAK2 phosphorylation (Flores-Morales 
et al. 2006).  PTP1b can interact with GHR and/or JAK2 in a GH-dependent manner 
and dephosphorylates residues on both molecules.  In addition, PTP-H1 can 
dephosphorylate the GHR (Flores-Morales et al. 2006).  The PIAS family is composed 
of 4 members: PIAS1, PIAS3, PIASx, and PIASy (Wormald & Hilton 2004).  PIAS1 
and PIAS3 bind Stat1 and Stat3, respectively, to inhibit DNA association.  The 
mechanism by which PIASx and PIASy inhibit Stat proteins is unknown, but neither 
PIAS prevents Stats from associating with DNA (Wormald & Hilton 2004).  It is not 
known whether the PIAS proteins are involved in down-regulation of GHR signaling.   
 The SOCS family contains eight known proteins, SOCS1 -7 and cytokine-
inducible SH2 domain containing protein (CIS), but only SOCS1-3 and CIS are 
induced by GH (Flores-Morales et al. 2006).  SOCS1 can bind JAK2 and block its 
kinase activity as well as regulate proteasomal degradation of activated JAK2 
(Ungureanu et al. 2002).  SOCS2 and CIS bind GHR and compete with Stat5 for 
binding to the receptor (Ram & Waxman 1999).  The mechanism for SOCS3 down 
regulation of GHR signaling is thought to involve SOCS3 binding to the GHR and 
inhibiting JAK2 kinase activity.  Moreover, GH regulation of SOCS1, SOCS2, and 
CIS is mediated via Stat5b (Woelfle & Rotwein 2004).   
The Stat proteins 
A major portion of the actions of GH are mediated via the IGF-I system.  
Current evidence indicates GH relies predominantly on Stat proteins, particularly 
Stat5, to alter the activity of the IGF-I system (Woelfle et al. 2005).  Therefore, this 
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section provides a brief overview of the Stat proteins with an emphasis on Stat5 and its 
regulation of the IGF-I system.   
Seven different members of the Stat family exist, Stats 1, 2, 3, 4, 5a, 5b, and 6.  
Genes for Stats 1 and 4 are located on chromosome 1, Stats 2 and 6 are on 
chromosome 10, and Stats 3, 5a, and 5b are on chromosome 11 (Miyoshi et al. 2001).  
The Stat family members share a conserved molecular structure that consists of an N-
terminal domain, followed by an -helical coiled coil domain, a DNA-binding 
domain, and a linker that connects to the C-terminus.  The SH2 domain is located 
within the C-terminus and is followed by a short region containing tyrosine residues.  
Activated Stat proteins bind to -interferon-activated sequences (GAS) and initiate 
transcription of target genes (Hennighausen & Robinson 2008).  The Stat5 proteins 
have been implicated in the regulation of hepatic GH-responsive genes such as IGF-I 
and ALS (Woelfle & Rotwein 2004).  Thus, these proteins will be described in more 
detail.  
Genes for Stat5a and Stat5b are located on mouse chromosome 11, and their 
promoters are oriented head-to-head and separated by only 10 kb.  The Stat5a gene is 
30 kb in length, contains 20 exons, and the start codon is located in exon 3.  The 
Stat5b gene is 50 kb in length, also contains 20 exons, but the start codon is located in 
exon 2.  The Stat5a gene has one promoter while Stat5b has two (Miyoshi et al. 2001).  
Stat5a and Stat5b share 96% homology at the protein level and contain 793 and 786 
amino acids, respectively.  The greatest divergence is found in the C-terminal region 
where transactivation occurs (Hennighausen & Robinson 2008).  Despite the similarity 
between these two isoforms, each has distinct functions in growth and development.   
GH regulation of IGF-I and ALS via Stat5 
 It has been well established that GH regulates the IGF-I system, with IGF-I 
and ALS, being the most responsive components.  Various GH deficient models have 
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been utilized to evaluate GH regulation of IGF-I.  In the rat model, hypophysectomy 
dramatically decreases hepatic IGF-I expression, but expression is restored by 
exogenous GH treatment (Murphy et al. 1987; Gronowski & Rotwein 1995; Roberts, 
Jr. et al. 1987; Hynes et al. 1987; Rotwein et al. 1993; Maiter et al. 1988).  Tissue 
IGF-I protein concentrations were lower in hypophysectomized rats than in normal 
rats.  IGF-I concentrations in the liver decreased the most and were increased 
significantly by GH treatment (D'Ercole et al. 1984). Two hours after treatment of 
hypophysectomized rats with GH, the 7.5 kb hepatic IGF-I transcript increased 10-
fold.  Response peaked at 4h and returned to baseline levels by 16h (Bichell et al. 
1992).  Dwarf lit/lit mice have low GH serum levels.  Hepatic IGF-I expression is 
markedly reduced in these animals, but it can be restored with administration of GH 
(Mathews et al. 1986).  In GH receptor knockout mice, hepatic IGF-I mRNA 
expression is 1-2% of that in normal mice (Lupu et al. 2001).   
Rotwein and coworkers demonstrated that GH effects on IGF-I mRNA 
occurred via stimulation of transcription (Bichell et al. 1992), but only recently have 
the molecular mechanisms been discovered.  Three distinct GH response elements 
(GHRE) that contain paired Stat5b binding sites have been mapped within the rat IGF-
I locus (Woelfle et al. 2003; Wang & Jiang 2005).  Two pairs are located within the 
second intron of the IGF-I gene while the other is located 77 kb 5’ to exon 1.  Using 
chromatin immunoprecipitation (ChIP) analysis, Wang et al. showed that Stat5b can 
bind both the intronic and 5’ distal sites with the IGF-I gene in a GH-dependent 
manner (Wang & Jiang 2005).  More recently, five additional Stat5 binding sites, 
distributed over 3 additional chromosomal regions of the IGF-I gene, have been 
identified.  Individually, these regions are capable of activating reporter gene 
expression via Stat5 binding, but a greater GH response is achieved when all five 
regions are activated (Eleswarapu et al. 2008).   
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GH regulation of ALS is also well understood.  ALS serum levels were 
reduced by 75% in 10-week old GH deficient, dw/dw rats (Baxter & Dai 1994).  
Acromegalic humans have 2.2-fold higher plasma ALS concentration than normal 
individuals whereas GH deficient adults have only 30% of normal levels (Baxter 
1990).  In GH deficient patients, plasma ALS levels are increased with GH 
replacement therapy (Thoren et al. 1997; Labarta et al. 1997).  In humans, acute GH 
treatment (single injection) had no effect on ALS mRNA or circulating levels, but a 
more chronic GH treatment (single injection for 5 consecutive days) increased hepatic 
ALS expression 85% and serum levels 1.5-fold (Olivecrona et al. 1999).   
When primary rat hepatocytes are treated with GH, ALS production increases 
in a dose dependent manner with a maximum ALS response at 30 ng/mL (Dai et al. 
1994; Scharf et al. 1996).  At 30 ng/mL of GH, ALS mRNA levels increased by 4-
fold, and ALS protein increased by 2-fold in primary hepatocytes.  It was also shown 
that IGF-I was unable to increase serum ALS levels in hypophysectomized rats 
(Fielder et al. 1996).  In hypophysectomized rats, hepatic ALS mRNA was reduced by 
over 90% and partially restored with GH treatment (Chin et al. 1994; Ooi et al. 1997).  
To confirm that GH stimulated ALS gene transcription, an ALS promoter reporter 
gene was transfected into rat hepatoma cells and primary rat hepatocytes.  GH 
treatment stimulated promoter activity 3-fold (Ooi et al. 1997). 
The molecular basis for this effect of GH has been studied using the mouse 
ALS promoter.  Using a luciferase reporter system, Boisclair et al. (1996) determined 
that a region between nucleotides –805 to –11 of the mouse ALS promoter contained a 
GH responsive element.  Serial deletions of the 5’ region of the ALS gene narrowed 
the GH response region to nt –653 and nt –483.  Computer analysis revealed two -
interferon activated sequences (GAS) sites, termed ALS-GAS1 and ALS-GAS2.  
These GAS-like sites have been shown to mediate the effects of various cytokines, 
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including GH, on gene transcription (Ooi et al. 1998).  Targeted deletion analysis 
revealed that ALS-GAS1 alone was required for GH activation of the mouse ALS 
promoter-luciferase reporter constructs.  Using electrophoretic mobility shift assays 
(EMSAs), Stat5a and Stat5b were identified as the nuclear proteins that bind the ALS-
GAS1 element after GH stimulation (Ooi et al. 1998).     
GH regulation of IGF-I and ALS via Stat5b has been confirmed in vivo.  In 
hypophysectomized rats infected with a control adenovirus, GH increased hepatic 
expression of IGF-I and ALS mRNA while infection with dominant-negative Stat5b 
adenovirus blocked IGF-I and ALS gene transcription.  In contrast, a constitutively-
active Stat5b adenovirus stimulated IGF-I and ALS expression even in the absence of 
GH (Woelfle & Rotwein 2004).  These data illustrate that Stat5b is both necessary and 
sufficient for GH-induced expression of IGF-I and ALS in liver.   
FUNCTIONAL ROLE OF THE GH-IGF SYSTEM  
The importance of GH and IGF-I in growth, metabolism, and development has 
been demonstrated using various genetically engineered mouse models.  Complete 
knockouts have provided significant insight into the role of the various components of 
the GH-IGF system.  More sophisticated methods of gene ablation (i.e. temporally or 
spatially specific) have allowed for further dissection of the roles of Stat5 and IGF-I.  
In the next section, I will discuss the information obtained from genetically modified 
mouse models with respect to the role of the GH-IGF system in postnatal growth, 
carbohydrate metabolism, and mammary gland development.   
Postnatal growth 
GH receptor knockout models 
The ability of the liver to respond to GH coincides with induction of hepatic 
GH receptor expression around 3 weeks of age in rodents.  Mice that have low 
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circulating GH or carry mutations in the GHR are normal weight at birth but exhibit 
growth retardation by 3 weeks of age (Le Roith et al. 2001).  
Null GHR model 
The GHR gene was disrupted by inserting a neomycin cassette to replace the 3’ 
end of exon 4 and a portion of intron 4/5.  Exon 4 encodes part of the GH binding 
domain (Zhou et al. 1997).  Body weight was similar between null GHR and wild type 
(WT) animals at birth, but by 4 weeks of age, null GHR weighed 45% less than WT 
mice.  At 10 weeks of age, null GHR weighed 55% less than WT mice, and this 
difference was maintained through 1 year of age (Kopchick & Laron 1999).  Body 
length and organ weights were decreased in null GHR mice.  Lastly, circulating IGF-I 
concentration was decreased ~90% (Zhou et al. 1997).  As described in the GHR 
signaling section, GH can signal through 3 distinct pathways.  Thus, inactivation of 
the GHR eliminates all downstream receptor signaling, making it difficult to identify 
pathways that are critical for postnatal growth.   
Knock-in GHR models 
Previous studies have mapped the intracellular domains of the GHR necessary 
for ERK and Stat5 activation.  ERK activation requires the proximal JAK2 activation 
domain which extends to approximately residue 391 of the GHR (Carter-Su et al. 
2000).  Stat5 signaling has been proposed to originate at Y498 and sites just proximal 
(Smit et al. 1996) or at sites distal to Y539 of the mouse GHR (Hansen et al. 1996).  
To elucidate the contribution of the various signaling pathways on postnatal growth 
and hepatic gene expression, Waters and coworkers (Rowland et al. 2005b; Rowland 
et al. 2005a) created knock-in models progressively deleting the intracellular domains 
of GHR.   
In the knock-in 569 mutant, the GHR was truncated at proline 569 in 
combination with mutation of tyrosines 539 and 545 to phenylalanine (Rowland et al. 
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2005b).  JAK2 and ERK activation were normal in the 569 mutants while Stat5 
activation was reduced to 30% of WT.  Postnatal growth rate was decreased 25% in 
both male and female 569 mutants.  Knock-in 569 mice had reduced hepatic 
expression of IGF-I and ALS (65% and 55% of WT, respectively) and reduced plasma 
IGF-I (20% of WT) (Rowland et al. 2005b).   
In the knock-in 391 mutant, GHR was truncated at lysine 391 (Rowland et al. 
2005b). JAK2 and ERK activation were normal in the 391 mutants while Stat5 
activation was undetectable.  Postnatal growth rate was decreased 50% and 40% in 
male and female 391 mutants, respectively.  These reductions were less than observed 
in the null GHR mice (58% and 50% reduction in males and females, respectively). 
Hepatic IGF-I and ALS expression was decreased to less than 10% of WT for both 
genes, whereas circulating IGF-I was less than 10%.  These results suggest that the 
growth promoting effects of GH depends primarily on Stat5 signaling while ERK 
plays a lesser role.   
Stat5 mutant models 
Upon initiation of the work described in this dissertation, three null Stat5 were 
described, null Stat5a, null Stat5b, and what was thought to be null Stat5a/b.  A 
number of tissue-specific knockouts have been described since.  These models have 
been created to dissect the functions of Stat5a and Stat5b.  Models relevant to growth 
will be discussed in the following section.     
Null Stat5 models 
Targeted disruption of the Stat5a gene was achieved by replacing the promoter 
sequence, the first non-coding exon, and the first two protein coding exons with a 
neomyocin cassette (Liu et al. 1997).  Offspring from heterozygous crosses segregated 
in the expected ratio of 1:2:1.  Homozygous Stat5a deficient mice appeared to develop 
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normally and were similar to heterozygous or WT animals with respect to size, 
activity, and fertility. 
The Stat5b gene was disrupted by inserting a neomycin cassette at a BamHI 
site that disrupts the codon for amino acid 181 (Udy et al. 1997).  Null Stat5b pups 
were normal size at birth, but by 4-5 weeks of age, body weight gain was reduced 27% 
in male but not female mice.   The growth curves of null Stat5b males overlapped with 
those of WT and null Stat5b females.  Circulating GH was elevated in 3 of 6 male 
mutant mice with no changes observed in female mice.  Plasma IGF-I was decreased 
30% in mutant mice, irrespective of sex (Udy et al. 1997).  Overall, data in Stat5a and 
Stat5b null mice suggest that GH-stimulated postnatal growth is mediated through 
Stat5b.   
Stat5b is the major mediator responsible for the effects of pulsatile GH 
secretion on sexually dimorphic growth and hepatic gene expression.  Male mice grow 
at a faster rate than females, and many hepatic genes are regulated in a sex-specific 
pattern (Davey et al. 1999).  In the mouse, this sexual dimorphism is regulated, in part, 
by the pattern of GH secretion (Gatford et al. 1998).  The male plasma GH pattern is 
characterized by discrete pulses separated by interpulses lasting at least one hour when 
no hormone is present.   In contrast, GH secretion is more continuous in the female 
mouse, consisting of frequent pulses with higher interpulse concentrations (MacLeod 
et al. 1991).  This profile of GH secretion also results in a sexually dimorphic pattern 
of hepatic Stat5 activation (Davey et al. 1999).  In the liver, the male pattern of GH 
secretion stimulates phosphorylation of Stat5b resulting in expression of male-specific 
genes while the female pattern of secretion results in near absence of Stat5b activation 
(Waxman et al. 1995; Gebert et al. 1999).  Consistent with that, loss of Stat5b resulted 
in changes in GH-regulated sexually dimorphic gene expression in the liver such that 
hepatic expression patterns in male null Stat5b mice were comparable to those in WT 
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females (Udy et al. 1997).  These data are also consistent with absence of Stat5b 
having a greater impact on male than female growth.   
Hypomorphic Stat5 models 
 In 1998, Ihle and co-workers (Teglund et al. 1998) attempted to knock out both 
Stat5a and Stat5b by inserting neomyocin- and hygromyocin cassettes into the first 
coding exon of the respective genes.  These mice were believed to be true knockouts, 
but it has since been established that this particular model expresses N-terminally 
deleted Stat5a and 5b proteins (Stat5aN and Stat5bN).  The corresponding mRNAs 
retain in-frame start codons at amino acid position 103 or 137, with the ATG at 
position 137 predominantly used (Kornfeld et al. 2008).  Despite expression of N-
truncated proteins, the growth phenotype of the individual Stat5aN and Stat5bN 
mutant models was essentially the same as the complete Stat5a and Stat5b mutant 
models described above (Liu et al. 1997; Udy et al. 1997; Teglund et al. 1998).  
Stat5aN and Stat5bN mutants were combined to create Stat5N mice.  Mice were 
observed at the expected Mendelian frequency; however, one-third of the mutant pups 
died within 48 hours of birth.  Male and female Stat5N mice weigh 30-40% and 20-
30% less than their WT littermates and experience a significant decline in circulating 
IGF-I.   
Recently Engblom et al. (2007) have shown that the transcriptional activity of 
Stat5 proteins in liver requires an interaction between Stat5 and the glucocorticoid 
receptor (GR).  Upon GH treatment, Stat5bN binds its binding sites on the IGF-I and 
ALS genes, but its ability to induce transcription is reduced (Engblom et al. 2007).  
ChIP assays demonstrate that the Stat5N protein is able to bind target DNA.  The 
Stat5N protein, however, does not associate with the GR as WT Stat5 does, which 
indicates that the N-terminal domain of Stat5 serves as a docking platform for GR 
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(Engblom et al. 2007).  In summary, Stat5b interacts with its transcription cofactor, 
the glucocorticoid receptor, to activate a subset of genes that regulate growth.  
Conditional Stat5 models 
 Presence of the Stat5a and Stat5b next to each other on chromosome 11 made 
it possible to ablate simultaneously both genes by inserting lox-P sites on either side of 
the 110 kb Stat5 locus.  Heterozygous Stat5 null mice were produced by crossing Stat5 
floxed females with a transgenic mouse line expressing a specific Cre transgene  
activated by mouse mammary tumor virus (MMTV) which resulted in Cre-mediated 
recombination in the germ cells (Cui et al. 2004).  Offspring from heterozygous Stat5 
crosses were examined at weaning, and only 0.5% of the weaned pups were null Stat5 
as compared to the expected 25%.  To determine when the lethality occurred, 
offspring were genotyped at E18.5 and within 12h of birth.  At E18.5 the expected 
25% of null Stat5 embryos were genotyped, but only 3.75% were still present within 
12 hours of birth.  The hematocrit of null E18.5 fetuses is significantly lower than their 
WT counterparts, suggesting that perinatal lethality is caused by severe anemia (Cui et 
al. 2004).   
 Two liver specific Stat5 null lines have been created.  The first line used a Cre 
transgene activated by the albumin promoter (Stat5AlbCre) (Holloway et al. 2007) while 
the second line used a Cre transgene under the control of the albumin promoter and -
fetoprotein enhancer (Stat5AlfpCre) (Engblom et al. 2007).  In contrast to the global 
Stat5 knockout, Stat5AlbCre mice are viable and fertile.  Interestingly, Stat5AlbCre mice 
grew at the same rate as their WT counterparts despite a 50% decrease in circulating 
IGF-I.  Alterations in expression of sexually dimorphic genes were also observed in 
the Stat5AlbCre mice, with knockout males displaying a hepatic gene profile similar to 
that of females (Holloway et al. 2007).   
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In contrast to the Stat5AlbCre mice, growth retardation was evident at 3 weeks of 
age in the Stat5AlfpCre mice (Engblom et al. 2007).  The differences observed in 
postnatal growth between the two lines probably can be explained by the different 
promoters used to induce Cre expression.  The albumin Cre promoter is only fully 
active after puberty, likely resulting in adequate Stat5 proteins in Stat5AlbCre mice until 
postnatal growth is mostly complete.  In contrast, the Alfp promoter is active 
perinatally leading to immediate Stat5 ablation 
 Muscle specific null Stat5 (Stat5Myf5Cre) lines were created by crossing floxed 
Stat5 mice with mice expressing the Cre gene driven by the myogenic factor 5 
promoter.  At 8 weeks of age, female and male Stat5Myf5Cre suffer a 12% and 20% 
decline in body weight, respectively, as compared to their WT counterparts.  X-ray 
analysis reveals that Stat5Myf5Cre mice have smaller skeletons.  When corrected for 
total body weight, percent lean and percent fat mass were similar in WT and 
Stat5Myf5Cre mice.  Muscle IGF-I mRNA and circulating IGF-I were decreased 60% 
and 15%, respectively, in Stat5Myf5Cre mice while GH levels were unchanged. 
IGF-I and ALS mutant models 
 GH effects on the IGF system are mediated predominantly via Stat5 regulation 
of IGF-I and ALS (Woelfle & Rotwein 2004).  The growth phenotypes observed in 
GHR and Stat5 mutant models could be attributed, at least in part, to down-regulation 
of IGF-I and ALS.  Therefore, the effects of IGF-I and ALS mutations on postnatal 
growth are described below. 
Null IGF-I models 
Various null IGF-I models have been developed using distinct gene targeting 
techniques (Baker et al. 1993; Liu et al. 1993; Powell-Braxton et al. 1993).  The 
growth phenotypes are similar among these different models (Liu et al. 2000a).  Null 
IGF-I mice are 40% smaller at birth, and most die soon after birth.  A significant 
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number of mutants do survive in a mixed background of MF1 and 129/sv, and these, at 
maturity, weigh only 30% of WT animals (Liu et al. 1998).  Global IGF-I knockouts, 
however, are inadequate to assess the relative role of endocrine vs. autocrine/paracrine 
IGF-I on growth. 
Conditional IGF-I and ALS mutant models 
To ascertain the role of endocrine IGF-I in postnatal growth, mice lacking IGF-
I specifically in the liver [LID (liver IGF-I deficient)] were created.  Two liver 
deficient models with similar phenotypes were created independently (Yakar et al. 
1999; Sjogren et al. 1999).  In one model, exon 4 of the IGF-I genes was flanked by 
loxP sites, and floxed animals were crossed with mice carrying Cre-recombinase 
regulated by the albumin promoter (Yakar et al. 1999).  In the second model, the 
floxed IGF-I mice were crossed with a Cre line driven by an inducible interferon 
promoter which eliminated IGF-I expression in both liver and spleen (Sjogren et al. 
1999).  Despite a 70% decrease in circulating IGF-I, LID mice did not display a 
growth phenotype.  LID mice also have significantly elevated levels of GH due to lack 
of negative feedback by circulating IGF-I (Yakar et al. 1999).   
For several years, these results led researchers to believe that endocrine IGF-I 
did not play a role in postnatal growth.  It has now been established that significant 
levels of circulating IGF-I are present in younger LID mice as the albumin promoter is 
not fully activated until ~4 weeks of age (Tang et al. 2005).  Using an alternative 
approach, rat IGF-I was expressed specifically in the liver of null IGF-I mice.  In this 
model, endocrine IGF-I was able to completely restore postnatal growth in null IGF-I 
mice which again suggests that endocrine IGF-I does indeed play a critical role in 
postnatal growth (Wu et al. 2008).   
Targeted deletion of the ALS gene in mice was achieved by replacing the 
coding regions of exon 1, intron 1, and ~1300 bp of exon 2 with a neomycin cassette 
23
(Ueki et al. 2000).  Mice lacking the ALS gene (ALSKO) suffered a 13-20% growth 
deficit.  In null ALS animals, circulating IGF-I and IGFBP-3 were decreased by 67% 
and 90%, respectively (Ueki et al. 2000).  These changes were attributed to increase 
plasma turnover as hepatic mRNA levels of IGF-I and IGFBP-3 were unchanged.   
When the liver deficient IGF-I model was crossed with the ALSKO model 
(LID+ALSKO), IGF-I levels were reduced more than 80%, and postnatal growth was 
decreased by 30% (Yakar et al. 2002).  The exact contribution of endocrine IGF to 
postnatal growth remains unknown, but it appears that a threshold level of circulating 
IGF-I is required. 
Differences in postnatal growth are quantified in a variety of ways.  Growth 
may reflect changes in body weight, body composition, or bone length.  GH and IGF-I 
are important regulators of bone growth and remodeling throughout life (Giustina et 
al. 2008).  GH can act directly on bone cells to stimulate proliferation in the growth 
plate, or it can act indirectly via upregulation of IGF-I expression in liver and bone 
(Ohlsson et al. 2000).  Local effects of IGF-I can also be independent of GH, and 
these effects are responsible for stimulation of osteoblasts and bone formation 
(Giustina et al. 2008).  The role of endocrine IGF-I in bone growth and remodeling 
has been evaluated in the LID, ALSKO, and LID+ALSKO models.  Femoral bone 
length was significantly shorter in these three models as compared to controls.  Mutant 
mice also suffered reduced bone mineral density and bone volume.  Exogenous IGF-I 
treatment was able to increase femoral length and restore the height of the growth 
plate in each of the three models (Yakar et al. 2002).  Thus, endocrine IGF-I is 







Growth hormone is an important modulator of insulin sensitivity.  GH 
stimulates pancreatic cell growth and insulin production and secretion (Liu et al. 
2004).  GHR mutant mice have increased insulin sensitivity while transgenic mice 
overexpressing GH are hyperinsulinemic and insulin resistant.  In null GHR mice, 
blood glucose and serum insulin concentrations are decreased 40% and 80%, 
respectively, suggesting a state of hypersensitivity to insulin (Dominici et al. 2000).  
Evaluation of the insulin signaling pathway showed that liver insulin receptor (IR) 
concentrations are increased along with increased IR phosphorylation in null GHR 
mice.  Despite low serum insulin concentrations, activation of the downstream IR 
signaling cascade (i.e. phosphorylation of IRS-1 and Shc and activation of PI3K) was 
similar to WT controls (Dominici et al. 2000).  The observed hypoinsulinemia in null 
GHR mice is a consequence of altered pancreatic islet structure and function (Liu et 
al. 2004).  Decreased cell proliferation and cell growth are responsible for the 
reduction in pancreatic cell mass in null GHR mice.  Furthermore, pancreatic insulin 
mRNA expression was reduced, leading to decreased insulin production.   
As expected, elevated GH levels yield the opposite effect on indices of 
carbohydrate metabolism.  In transgenic mice over-expressing bovine growth hormone 
(bGH-TG), plasma insulin levels were increased nearly 5-fold while plasma glucose 
was normal (Dominici et al. 1999a).  Insulin receptor concentration was decreased 
while IR, IRS-1, and PI3K activity were maximally stimulated under basal conditions 
in both liver and muscle of bGH-TG mice.  Exogenous insulin treatment increased IR 
and IRS-I phosphorylation and PI3K activity in liver and muscle of WT mice while no 
additional stimulation was observed in bGH-TG (Dominici et al. 1999b; Dominici et 
al. 1999a).  Thus, the bGH-TG mice were insensitive to insulin treatment.   
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IGF-I and ALS models 
 Carbohydrate metabolism has been studied in the LID mice.  In this model, the 
lack of negative feedback by circulating IGF-I increased circulating GH 
concentrations from 2.8 to 17.8 ng/mL in LID mice (Yakar et al. 2001).  Insulin levels 
were increased 4-fold, and LID mice were less sensitive to exogenous insulin.  In LID 
mice, insulin-stimulated IR and IRS-1 phosphorylation was normal in liver and 
adipose tissue but impaired in muscle.  Thus, the insulin insensitivity in LID mice is 
muscle specific.  Treatment of LID mice with exogenous IGF-I reduced plasma GH 
and improved insulin sensitivity (Yakar et al. 2001).   
 To determine if this improvement was due to increased IGF-I or reduced GH, 
LID mice were crossed with GH-antagonist (GHa) transgenic mice (Yakar et al. 
2004).  GHa mice were generated by introducing a point mutation in the GH gene 
which prevents proper dimerization of the GHR, blocking GH action (Chen et al. 
1991).  When insulin sensitivity was evaluated using the hyperinsulinemic-euglycemic 
clamp technique, LID mice exhibited impaired insulin sensitivity in muscle, liver, and 
adipose tissue.  Insulin sensitivity was improved in LID+GHa mice, suggesting that 
elevated GH levels are the major cause of insulin resistance in LID mice (Yakar et al. 
2004). 
 Insulin sensitivity is also dependent on IGF-I availability.  When LID mice are 
crossed with the ALSKO mice (LID+ALSKO), circulating IGF-I concentrations are 
reduced to only ~15% of WT, and GH levels increase above those seen in LID mice 
(Haluzik et al. 2003).  Yet, LID+ALSKO mice have improved whole body insulin 
responsiveness (Haluzik et al. 2003).  In this case, improved insulin action was caused 
by an increase in plasma concentration of free IGF-I, a potent insulin sensitizer in 
skeletal muscle and adipose tissue.     
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Recent studies have identified a mechanism involving PI3K whereby GH 
antagonizes insulin signaling.  PI3K is a heterodimer composed of the p85 subunit and 
the catalytic subunit p110.  The p85 subunit serves two functions.  First, it provides a 
binding domain for IRS proteins, and second, it regulates the activity of the p110 
catalytic subunit (Dominici et al. 2005).  Increased expression of p85 increases the 
pool of free p85 which competes with the p85-p110 heterodimer for binding sites on 
IRS-1.  As a result, PI3K activity decreases when free p85 is in excess (Biddinger & 
Kahn 2006).  Excess GH induced p85 expression in skeletal muscle.  Muscle p85 
mRNA was increased in skeletal muscle of LID mice, but normalized when LID mice 
were treated with a GH antagonist.  Moreover, GH was unable to induce insulin 
resistance in p85 heterozygous mice (Barbour et al. 2005).   
A similar mechanism of GH induced insulin resistance has been demonstrated 
in white adipose tissue (WAT).  Chronic GH over-expression increased p85 mRNA 
and protein expression in WAT while p85 mRNA was decreased in GH-deficient 
lit/lit mice.  Furthermore, PI3K activity was decreased when GH is in excess and 
increased when GH is deficient (Del Rincon et al. 2007).  These results suggest that 
one mechanism whereby GH induces insulin resistance in skeletal muscle and WAT is 
by increasing the amount of free p85 monomers, which in turn, leads to reduced 
PI3K activity.   
Stat5 models 
GH is required for -cell proliferation and stimulation of insulin expression 
and secretion (Liu et al. 2004).  The Stat5 proteins are activated by GH in insulin-
producing INS-1 cells and in cultured rat islets (Friedrichsen et al. 2001).   These 
observations suggest that some of the effects of GH on insulin secretion are mediated 
via Stat5.   
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In mice lacking hepatic Stat5 (Stat5AlbCre), plasma IGF-I was reduced by 50%, 
and GH levels were significantly elevated.  In 10 week old Stat5AlbCre mice, the levels 
of glucose, triglycerides and free fatty acids (FFA) were similar to WT, but insulin 
levels were significantly elevated (Cui et al. 2007).  Glucose clearance was impaired 
and insulin sensitivity was reduced in Stat5AlbCre mice.  By 17 months of age, serum 
glucose, insulin, and triglyceride levels were all increased in Stat5AlbCre mice.   
Furthermore, mutant mice were glucose intolerant and were severely insulin resistant 
(Cui et al. 2007).     
Carbohydrate metabolism also was examined in mice lacking Stat5 in muscle 
(Stat5Myf5Cre).  In contrast to the hepatic Stat5 mutant, GH levels were not increased in 
Stat5Myf5Cre mice (Klover & Hennighausen 2007).  Moreover, serum glucose, insulin 
and FFA were not different between Stat5Myf5Cre mice and controls, but triglyceride 
levels were significantly elevated.  Glucose clearance was impaired in Stat5Myf5Cre 
mice while insulin sensitivity was maintained (Klover & Hennighausen 2007).  
Pancreatic specific null Stat5 mice (Stat5Pdx1Cre) were created by crossing 
floxed Stat5 mice with mice expressing Cre driven by the pancreatic and duodenal 
homeobox 1 (Pdx1) promoter (Lee et al. 2007).  Stat5Pdx1Cre mice are the same size as 
WT mice and have normal pancreatic development.  Glucose homeostasis was 
evaluated over a 15 month period in WT and mutant mice.  Circulating insulin, 
glucose, and glucagon were similar between WT and Stat5Pdx1Cre mice as was 
pancreatic insulin mRNA and protein expression.  Mild glucose intolerance was 
observed in aged or pregnant Stat5Pdx1Cre mice (Lee et al. 2007).  These results 
demonstrate that Stat5 is not required for pancreatic development but may be 




Mammary gland development 
The mammary gland undergoes extensive morphological and biochemical 
changes during postnatal life.  These changes are specific to the virgin state, 
pregnancy, lactation, and involution.  During the first phase, the ducts elongate to fill 
the mammary fat pad (Hovey et al. 2002).  Development during pregnancy is 
characterized by further branching of the ducts and alveolar differentiation.  During 
lactation, the alveoli expand to completely fill the gland, and active milk secretion is 
established (Brisken 2002).  Upon weaning, the lactating gland undergoes involution 
whereby remodeling returns the gland to its pre-pregnancy state (Lamote et al. 2004).  
These dynamic changes are under strict hormonal control by various steroid and 
peptide hormones (Richert et al. 2000).  In the next few pages, I will discuss changes 
during each phase with a focus on the roles played by the GH-IGF-I system.   
Virgin State 
At birth, the mammary gland consists only of a few rudimentary ducts.  The 
rudimentary ductal structure remains inactive until approximately 3 weeks of age 
when the ovaries begin secreting estrogen (Hovey et al. 2002).  The growing ducts of 
the pubertal animal have club-shaped structures at their tips, called terminal end buds 
(TEBs).  They are composed of two cell types:  the outer cap cells that give rise to 
basal cells and the body cells that give rise to luminal cells (Howlin et al. 2006).  The 
TEBs are the primary epithelial structures and are the sites of ductal elongation and 
branching in the mammary gland.  At regular intervals, some TEBs invaginate to form 
two TEBs, both of which continue to grow, forming a branched structure.  This 
continues until the entire fat pad is filled with a simple ductal tree (Brisken 2002). 
The GH-IGF-I axis plays a critical role in mammary ductal elongation 
(Kleinberg 1997; Kleinberg et al. 2000; Hadsell et al. 2002).  GHR is expressed in the 
stromal compartment of the mammary gland.  In the pubertal, virgin animal, IGF-I, 
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and IGF-IR expression is detected in the TEBs, and IGF-I is also expressed in the 
stroma surrounding the TEBs (Richert & Wood 1999).  In post pubertal mice, IGF-IR 
mRNA was also detected in the ductal epithelial cells.  IGFBP-3 and -5 are expressed 
in the TEBs and ductal epithelium (Wood et al. 2000).   
GH binds GHR in the stromal compartment of the mammary gland, 
upregulating IGF-I expression.  IGF-I then binds to its receptor on epithelial cells to 
promote ductal development and TEB formation (Kleinberg et al. 2000). Ruan and 
colleagues (Ruan et al. 1992) demonstrated that IGF-I can substitute for GH mediated 
mammary gland development in hypophysectomized rats.  Consistent with these data, 
null GHR mice have impaired ductal outgrowth and limited side-branching (Gallego et 
al. 2001).  
In mice lacking either IGF-I or IGF-IR, TEB formation and ductal growth was 
diminished as a result of decreased cellular proliferation (Ruan & Kleinberg 1999; 
Bonnette & Hadsell 2001).  Administration of a GH antagonist decreased hepatic 
mRNA expression and circulating IGF-I levels in virgin female mice and delayed 
mammary ductal growth.  This delay was associated with a decrease in TEB numbers 
and reduced branching of the ductal tree (Divisova et al. 2006).  Taken together, these 
data suggest that GH acts indirectly on the mammary gland by upregulating local IGF-
I expression.  In addition, estrogen enhances both GH-induced expression of IGF-I 
mRNA in the mammary stroma and the stimulatory effect of IGF-I on mammary 
development (Ruan et al. 1995).   
Pregnancy and lactation 
Massive proliferation of ductal branches and formation of alveolar buds occur 
in early pregnancy (Brisken 2002).  During the second half of pregnancy, alveolar 
buds expand into alveoli which progressively differentiate into milk secreting 
structures (Brisken & Rajaram 2006).  By early lactation, over 70% of the gland is 
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occupied by the secreting epithelium, leaving ~30% of the gland occupied by 
adipocytes.  Once lactation is established, the alveoli expand to completely fill the 
gland (Richert et al. 2000).   
The precise roles of GH and the IGF-I system in regulating mammary 
development during pregnancy and lactation are largely unknown.  In mid-pregnancy, 
IGF-I mRNA expression is detected in the stromal cells immediately surrounding the 
ducts.  In late pregnancy, IGF-I and IGF-IR mRNA are widely expressed in ductal and 
alveolar epithelium (Richert & Wood 1999).  During pregnancy, IGFBP-3 expression 
is detected in the outer layer of epithelial cells and decreases during lactation.  IGFBP-
5 expression is detected in the stromal compartment surrounding the primary ductal 
tree and lobulo-alveolar structures during pregnancy.  Expression decreases by 
lactation d2 and remains low during lactation (Allar & Wood 2004).   
Reduced stromal IGF-I impaired alveolar bud development in early pregnancy 
(Loladze et al. 2006).  By mid-pregnancy, the mammary gland had a hyperplastic 
phenotype characterized by alveoli lacking a defined lumen and increased nuclei per 
alveolus   Reduced epithelial expression of IGF-I mRNA in late pregnancy had little 
effect on mammary development (Loladze et al. 2006).   
Stat5 proteins are critical for mammary development during pregnancy.  Both 
GH and prolactin activate Stat5 in the mammary gland (Gallego et al. 2001).  Null 
Stat5a females were fertile and gave birth to live pups, but they were unable to nurse 
their young (Liu et al. 1997).  Further investigation of mammary development 
revealed that mutant females failed to develop lobulo-alveolar structures, and 
expression of the milk proteins -lactalbumin and whey acid protein (WAP) was 
decreased (Liu et al. 1997; Teglund et al. 1998).  Interestingly, Stat5b protein levels 
were decreased in null Stat5a mice and were unable to compensate for the loss of 
Stat5a (Liu et al. 1997). 
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Null Stat5b mice consistently aborted between d8 – d17 of pregnancy.  
Administration of progesterone maintained pregnancy in null Stat5b females, but 
nevertheless, they appeared to have impaired mammary gland development because 
dams were unable to successfully nurse their pups (Udy et al. 1997).  Female Stat5N 
mice had impaired corpora lutea development and were infertile.  As a result of the 
infertility, mammary gland development during pregnancy and lactation could not be 
evaluated (Teglund et al. 1998). 
Mammary specific deletion of both Stat5a and 5b was performed using two 
different Cre systems.  In the first case, mammary Stat5 expression was ablated before 
pregnancy by stimulating mammary Cre expression with the MMTV promoter (Cui et 
al. 2004).  All dams were unable to nurse their pups.  Loss of Stat5 did not affect 
ductal outgrowth or primary and secondary branching.  However, lobulo-alveolar 
structures failed to form, demonstrating that proliferation of mammary secretory 
epithelium requires Stat5 (Cui et al. 2004).   
 To determine whether Stat5 was necessary for the survival of the fully 
differentiated mammary epithelium, Stat5 was eliminated in the mammary during late 
pregnancy after lobulo-alveolar development occurred, using Cre driven by a WAP 
promoter (Stat5WAPCre).  These dams were able to nurse their litters, but histological 
evaluation of the glands revealed decreased alveolar density.  Those mammary 
epithelial cells that lacked Stat5 de-differentiated and were eliminated via apoptosis 
(Cui et al. 2004).   
Involution 
Removal of milk from the mammary gland is necessary for the maintenance of 
lactation (Stein et al. 2007).  Therefore, the lactating gland involutes to its pre-
pregnancy form upon weaning.  The process of involution involves apoptosis of the 
mammary epithelial cells and structural remodeling of the gland (Lamote et al. 2004).  
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In rodents, this stage is typically studied using forced weaning, where the dam is 
allowed to lactate for 8-12 days and then the pups are removed (Richert et al. 2000).  
The first phase of involution is characterized by an accumulation of milk in alveoli 
and minimal cell death.  During this early stage, involution is reversible and lactation 
can be re-established if pups are returned within 2 days of removal (Lamote et al. 
2004).  As involution proceeds, the epithelial cells of the alveoli undergo apoptosis.  
By day 4 of involution, the alveoli begin to collapse, the basement membrane is 
degraded, and macrophages invade.  By this time, fat-filled adipocytes reappear.  By 
d21, the gland has returned to its pre-pregnancy state (Richert et al. 2000).    
 Involution is thought to be facilitated by attenuation of IGF-I signaling.  This 
attenuation appears to be dependent on the induction of mammary IGFBP-5 synthesis. 
On day 2 of involution, IGFBP-5 concentration in milk increased 50-fold in the rat 
(Tonner et al. 1997).  In primary mammary epithelial cultures, IGFBP-5 inhibited 
IGF-I mediated cell proliferation (Marshman et al. 2003).  Similar results were 
obtained in vivo using a transgenic mouse model that overexpressed IGFBP-5 
specifically in the mammary (Tonner et al. 2002).  During the first 10 days of 
lactation, mammary cell number and milk synthesis were both decreased, and 
mammary cell proliferation was impaired.  The concentration of pro-apoptotic factors, 
caspase-3 and plasmin, increased while pro-survival factors, Bcl-2 and Bcl-XL, 
decreased.  Mammary development was rescued when animals were treated with a 
form of IGF-I that has low affinity for IGFBP-5 (Tonner et al. 2002).  Finally, 
involution was evaluated in null IGFBP-5 mice.  In this model, involution was delayed 
after forced weaning.  Appearance of apoptotic cells and the reappearance of 
adipocytes were both retarded in mutant mice (Ning et al. 2007).  Reciprocally, 
overexpression of IGF-I in the mammary glands of lactating mice delayed the 
involution process (Neuenschwander et al. 1996).   
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SUMMARY 
 The functional importance of the GH-IGF-I system on postnatal growth, 
carbohydrate metabolism, and mammary development has been reviewed above.  GH 
can act directly on target tissues, or it can act indirectly by stimulating IGF-I 
production.  The IGF-I mediating effects can arise locally or can be produced in the 
liver.   Effects of GH are mediated through the GH receptor.  Binding of GH to its 
receptor leads to activation of JAK2.  This is followed by JAK2 dependent activation 
of various signaling cascades (Lanning & Carter-Su 2006).  The downstream 
mediation of the growth promoting effects of GH have been attributed predominantly 
to the Stat5a and 5b proteins (Waters et al. 2006).   
Genetic mouse models have been created in which each individual Stat5 gene 
is ablated (Liu et al. 1997; Udy et al. 1997).  These models show that Stat5a is 
absolutely required for proper mammary gland development during late pregnancy 
and lactation, but Stat5a appears to play no role in regulation of growth (Liu et al. 
1997).  On the other hand, Stat5b plays important roles in regulating sexually 
dimorphic growth rates and male specific hepatic gene expression (Udy et al. 1997).  
Stat5b has also been shown to mediate the positive effects of GH on hepatic 
production of major components of the circulating IGF-I system, namely, IGF-I and 
ALS (Woelfle & Rotwein 2004).  So far, no studies have ever directly assessed 
whether growth effects of exogenous GH were also lost in Stat5 deficient mice.  
Chronic administration of GH has been used to evaluate the responsiveness of various 
GH/IGF-I mutant models to exogenous GH (Liu & LeRoith 1999; Liu et al. 2000b; 
Fielder et al. 1996).  Therefore, the objective of Chapter 3 was to test whether 
exogenous GH could stimulate not only overall growth of Stat5N mice but also other 
GH-dependent responses such as organ growth and insulin resistance.  
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In the case of most tissues, IGF-I remains near its cellular site of production 
and represents the autocrine/paracrine arm of the IGF-I system (Le Roith et al. 2001).  
These IGF-I molecules are usually bound to one of six IGF binding proteins (Jones & 
Clemmons 1995; Stewart & Rotwein 1996).  Liver-derived IGF-I, on the other hand, 
is secreted in plasma and represents the endocrine arm of the IGF-I system.  In 
postnatal animals, circulating IGF-I is bound in a 150 kDa ternary complex composed 
of one molecule each of IGF-I, IGFBP-3 or -5, and ALS (Baxter 1988; Twigg & 
Baxter 1998). 
ALS is thought to function exclusively as a component of the circulating IGF-I 
system.  It is responsible for formation of ternary complexes in circulation, building a 
reservoir of circulating IGF-I, and preventing its insulin-like effects (Zapf et al. 1995).  
Characterization of the null ALS mutant revealed a functional role for ALS in 
postnatal growth and metabolism (Ueki et al. 2000; Haluzik et al. 2003), but the role 
of ALS in mammary gland development has not been studied.   
The mammary gland undergoes extensive morphological and biochemical 
changes during postnatal life. These dynamic changes are under strict hormonal 
control by sex steroid hormones and various growth factors (Richert et al. 2000).  GH, 
IGF-I, and IGFBPs play critical roles during all phases of postnatal mammary gland 
development.  GH-induced expression of IGF-I in the mammary fat pad stimulates 
ductal elongation in the virgin state (Walden et al. 1998).  IGF-I is also important in 
early pregnancy, promoting proliferation of ductal branches and formation of alveolar 
buds (Loladze et al. 2006).  Furthermore, involution is thought to be facilitated by 
attenuation of IGF-I signaling, and this attenuation appears to be dependent on the 
induction of mammary IGFBP-5 synthesis (Flint et al. 2003). 
The only known function of ALS is to bind binary complexes of IGF-I and 
IGFBP-3 or -5 in plasma and to give rise to a substantial plasma IGF-I reservoir.  IGF-
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I, IGFBP-3, and -5 are expressed in the mammary gland, but whether ALS synthesis 
occurs remains unknown.  Similarly, the possibility that ALS has a functional role on 
mammary gland development has not been examined.  Therefore, the objective of 
Chapter 4 was to evaluate the role of ALS in mammary gland development using the 








Growth hormone (GH) plays an essential role in the promotion of growth, 
development, and metabolism during postnatal life (Le Roith et al. 2001).  GH exerts 
these positive effects by acting directly on target tissues and indirectly by stimulating 
the synthesis of insulin-like growth factor (IGF-I) in liver and other tissues (Le Roith 
et al. 2001).  Effects of GH are mediated through the growth hormone receptor 
(GHR).  Binding of GH to its receptor leads to activation of Janus kinase 2 (JAK2).  
This is followed by JAK2 dependent activation of various signaling cascades (Lanning 
& Carter-Su 2006).  The downstream mediation of the growth promoting effects of 
GH have been attributed predominantly to the signal transducers and activators of 
transcription (Stat) 5a and 5b proteins (Waters et al. 2006).   
Null mutations for each of the Stat5 isoforms alone or in combination have 
been developed.  The single mutant models have demonstrated that Stat5a is important 
in mammary development (Liu et al. 1997) while Stat5b is necessary for sexually 
dimorphic body growth rates and for male specific hepatic gene expression (Udy et al. 
1997).  Stat5b has also been shown to mediate the positive effects of GH on hepatic 
production of major components of the circulating IGF-I system, namely, IGF-I and 
ALS (Woelfle & Rotwein 2004).  Moreover, plasma IGF-I concentrations are lower in 
mice lacking Stat5b (Udy et al. 1997).  It is unknown to what extent extra-hepatic GH-
stimulated IGF-I production also depends on this mechanism.  It is also unknown 
whether other actions of GH, such as induction of insulin resistance, depend on the 
presence of Stat5.   
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Therefore, our aim was to test whether exogenous GH could stimulate growth, 
development, and insulin resistance in Stat5 mutant mice.  For this study, we used the 
mouse model developed by Ihle and colleagues (Teglund et al. 1998), which combine 
hypomorphic mutations for both Stat5a and 5b (Stat5N).  Stat5N mice are viable after 
birth unlike mice missing both Stat5a and 5b.  Moreover, Stat5N mice recapitulate the 
major defects seen in the mice harboring single null Stat5 mutations (i.e., impaired 
mammary development and growth) (Teglund et al. 1998). 
MATERIALS AND METHODS 
Stat5N mice and genotyping analysis 
Experimental procedures involving live animals were conducted with the 
approval of the Cornell University Institutional Animal Care and Use committee.  The 
facility was kept at constant temperature (~22C) and humidity (~65%) with 
controlled lighting (14 h light/10 h dark cycle).  All animals were offered water and 
fed a standard rodent chow (Harlan Tekland 8640 containing 22% protein, 5% fat, 
Harlan, Madison, WI) ad libitum unless otherwise noted.  Mice that express N-
terminally deleted Stat5a and Stat5b (Stat5N) proteins were studied. Heterozygous 
breeding pairs were used to generate offspring for all experiments.  This mating 
strategy was used because Stat5N mice are infertile (Teglund et al. 1998).   
At weaning, tail biopsies were taken to determine genotypes.  DNA was 
isolated using the HotSHOT method (Truett et al. 2000).  Briefly, tail biopsies (~4 
mm) were incubated at 95C for 1 h in 100 L hydrolysis solution (25 mM NaOH, 0.2 
mM EDTA, pH 12).  Samples were neutralized with an equal volume of 40 mM Tris-
HCl, pH 5.0.  Two L of neutralized solution were amplified in a final volume of 20 
L containing 1X Taq PCR buffer (10 mM Tris-HCl, 50 mM KCl, 0.1% Triton x-100 
and 1.2 mM MgCl2), 0.2 mM dNTPs and 0.625 units of Taq polymerase (Promega, 
Madison, WI).  The Stat5a and Stat5b genes are located adjacent to one another on 
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mouse chromosome 11, and the transcriptional start sites are located within 10 kb of 
each other (Hennighausen & Robinson 2008).  Because of their close proximity, these 
genes behave as a single 110 kb locus, and thus a single PCR amplifying the Stat5b 
gene was performed.  Primer sequences for the Stat5b locus were from Teglund et al. 
(1998).  For genotyping, forward primers F-11 (5’- TCA AAC ACA CCT CAA TTA 
GTC C -3’) and TKp (5’- GCA AAA CCA CAC TGC TCG AC -3’) were used with 
the reverse primer R8 (5’- GGA GAT CTG CTG GCT GAA AG -3’).  Final primer 
concentrations were 0.25 M for each.  The reaction was first denatured at 94C for 
10 minutes, followed by 29 cycles of 94C for 1 minute, 55C for 30 seconds, and 
72C for 1 minute with a 5 second extension per cycle.  A last cycle was performed 
identically except that the 72C step lasted 7 minutes.  This combination of primers 
yielded bands of 321 bp for the wild type (WT) Stat5b allele and 132 bp for the 
Stat5N allele.  Products were visualized by agarose gel electrophoresis.   
GH activation of truncated Stat5  
 Wild type and Stat5N male mice (n=5 animals/genotype) were given a single 
intra-peritoneal injection of saline or recombinant bovine GH [GH, 4 g/g body 
weight (BW)].  Mice were sacrificed 15 minutes later by carbon dioxide asphyxiation. 
Liver, gonadal fat pad, and gastrocnemius muscle were dissected and snap-frozen 
immediately in liquid nitrogen.   
Western immunoblot analysis 
 Total cellular extracts were prepared by homogenizing tissues (100 mg liver 
and muscle, 200 mg adipose) in 1 mL lysis buffer (10 mM Tris, 1.0% Triton x-100, 
150 mM NaCl, 1 mM EGTA, 1 mM sodium orthovanadate, 1 mM sodium 
pyrophosphate, 10 mM sodium fluoride, 10 g/mL leupeptin, 1 mM phenyl methyl 
sulfonyl fluoride).  Homogenates were clarified twice by centrifugation (10,000 g for 
20 minutes at 4C). 
39
The protein content of the extracts was measured by the BCA protein assay 
(Pierce, Rockford, IL).  Thirty-five µg of protein were electrophoresed on 10% 
sodium dodecyl sulphate (SDS) polyacrylamide gels and transferred overnight to 
nitrocellulose membranes (Schleider, and Schuell Inc., Keene, NH).  The membranes 
were blocked for 1h at room temperature with Tris-buffered saline supplemented with 
Tween-20 (TBST, 0.05 M Tris pH 7.4, 0.2 M NaCl, 0.1% Tween-20) containing 5% 
w/v non fat dried skim milk.  Membranes were incubated with primary antibodies 
specific for STAT5 phosphorylated on tyrosine 694 (pY694 STAT5, Cell Signaling 
Technology, Inc., Beverly, MA) and total Stat5 (Santa Cruz, Santa Cruz, CA).  
Primary antibodies were diluted in blocking solution (pSTAT5, 1:500 and total Stat5, 
1:2000).  Following incubation, membranes were washed five times (5 min each) in 
TBST, then incubated with HRP-conjugated goat-anti rabbit secondary antibody 
(KPL, Gaithersburg, MD) at a 1:5000 dilution in blocking solution for 1 h at room 
temperature.  Signals were detected with LumiGlo chemiluminescence reagents (KPL) 
and autoradiography. 
Chronic GH treatment of Stat5N 
A total of 29 WT and 31 Stat5N mice were studied.  Mice were randomly 
allocated to receive twice daily subcutaneous injections of saline or recombinant 
bovine GH (GH, 3 g/g BW/injection).  Treatments started on postnatal day 35 and 
continued for 4 weeks.  On a daily basis, animals were weighed and injected at 0900h 
and injected again at 2100h.  On the last day of treatment, animals were injected at 
0900h and food was removed.  The animals were euthanized 4h later by carbon 
dioxide asphyxiation.  Blood was collected immediately by cardiac puncture, and 
processed to plasma by the addition of heparin (60 U/ml).  Nose to anus length was 
measured using digital calipers.  Liver, kidney, spleen, gonadal fat pad, and 
gastrocnemius muscle were dissected, blotted dry, weighed, and snap-frozen 
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immediately in liquid nitrogen.  Plasma and tissues were stored at –20C and -80C, 
respectively.   
Analysis of IGF-I, insulin, and glucose in plasma 
Plasma IGF-I concentrations were measured using a rat IGF-I double antibody 
radioimmunoassay (RIA) purchased from Beckman Coulter (Webster, Texas).  
Analysis was performed as recommended by the manufacturer using 25 L plasma for 
acid-ethanol extraction.  The range of the standard was 150-4500 ng/mL.   
Plasma insulin concentrations were measured using a two-day disequilibrium 
rat insulin RIA (Sensitive Rat Insulin RIA kit, Linco Research, Inc., St. Louis, MO). 
The range of the standard was 0.02-1.0 ng/mL.   
Plasma glucose concentrations were measured by the glucose oxidase method 
using reagents from Sigma (St. Louis, MO).  The assay was performed in duplicate 
using 2 L of plasma.  Absorbance was read at 450 nm using a microplate reader 
(VERSAmax, Molecular Devices Corp., Sunnyvale, CA) driven by the SOFTmax 
PRO software (Molecular Devices). 
Northern blot analysis 
For Northern analysis, total RNA was extracted from liver by affinity 
chromatography according to manufacturer recommendations (RNeasy Mini Kit, 
Qiagen Inc., Valencia, CA).  The concentration of total RNA was determined by 
measuring absorbance at 260 nm, and RNA quality was assessed on formaldehyde 
agarose gels by staining with Sybr Green II stain (Molecular Probes, Eugene, OR).  
Total RNA (10 g) was electrophoresed on a 1% denaturing agarose gel 
containing 0.66 M formaldehyde, 1X MOPS (0.04 M 3-N-Morpholino-
propanesulfonic acid, 0.05 M sodium acetate, 0.001 M EDTA, pH 8.0).  
Electrophoresis was performed for 2 h at 80 V in 1X MOPS.  Total RNA was 
transferred onto a nylon membrane (GeneScreenTM, NEN Research Products) by 
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capillary transfer in 10X SSPE (1X SSPE = 0.18 M NaCl, 1 mM EDTA, pH 8.0; 1 
mM sodium phosphate).  Membranes were irradiated in a UV crosslinker at 120 
mJ/cm2, dried for 1 h at 60C, and stored at -20C until hybridization. 
 To detect ALS and IGF-I mRNA in liver, membranes were prehybridized at 
50C in a solution of 50% formamide/dextran sulfate, 5X SSPE, 10X Denhardt’s [1X 
Denhardt’s = 0.02% bovine serum albumin (BSA), 0.02% ficoll 400, 0.02% 
polyvinylpyrrolidone (MW 40,000)], 100 mg/ml salmon sperm DNA, and 1% SDS.  
The ALS probe used was a 750 bp DNA fragment corresponding to nt +163 to nt +915 
of the mouse ALS cDNA (numbering relative to A+1TG) (Ueki et al. 2000), and the 
IGF-I probe was a 406 bp fragment corresponding to nt -22 to +384 of the rat IGF-I 
DNA (numbering relative to A+1TG). The probes were labeled with [-32P] dCTP 
(3000 Ci/mmol) by random priming (Prime-It, Stratagene, La Jolla, CA).  After a 2 h 
prehybridization, the DNA probes (~1 x 106 dpm/ml) were added and the 
hybridization continued overnight.  After hybridization, membranes were washed 
twice for 30 minutes in a solution of 2X SSPE/0.2% SDS at room temperature, and 
twice for 15 minutes in a solution of 0.1X SSPE at 60C.   
The 18S ribosomal RNA was detected with a low specificity labeled 
oligonucleotide (Deindl 2001).  The oligo sequence is 5’-CGG AAC TAC GAC GGT 
ATC TG-3’ and was labeled with [-32P] dATP (3000 Ci/mmol) using T4 
polynucleotide kinase (Promega, Madison, WI).   Hybridizations were conducted at 
42C in a solution of 50% formamide/dextran sulfate, 5X SSPE, 10X Denhardt’s, 1% 
SDS.  Hybridizations were performed with the labeled probe (~2 x 106 dpm/ml) mixed 
with a 10-fold molar excess of unlabelled oligonucleotide.  Membranes were washed 
three times each with 2X SSPE/0.2% SDS at 45C.   
For visualization of ALS, IGF-I, and 18S signals, membranes were exposed to 
x-ray film (Fuji Medical Systems USA, Inc., Stanford, CT).  Signals were quantified 
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by phosphoimaging using a FUJIX BIO-IMAGING ANALYSER BAS1000 (Fuji 
Photo Film Co., Ltd.).     
Real-time PCR Analysis  
For real-time PCR assays, liver (20 mg), gonadal fat (150 mg), and 
gastrocnemius muscle (30 mg) were homogenized in 1 mL Qiazol reagent (Qiagen 
Inc., Valencia, CA).  Total RNA was purified by affinity chromatography, combined 
with an on-column RNase-free DNase treatment (Qiagen).  RNA concentration and 
quality were assessed by RNA Nano LabChip Kit (Agilent Technologies, Palo Alto, 
CA).   
Real-time SYBR green PCR assays were used to measure transcript abundance 
of p85 regulatory subunit of phosphotidylinositol 3-kinase (PI3K) and 18S in liver 
using the primers listed in Table 3.1.  Real-time SYBR green PCR was also used to 
measure IGF-I, PI3K, and 18S in gonadal fat pad and gastrocnemius muscle.  Briefly, 
total RNA (2 g) was reverse-transcribed in a 20 L volume using the High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA) according to 
the manufacturer’s recommendation.  PCRs were performed in duplicate in a 25 L 
volume using Power SYBR Mix (Applied Biosystems).  Reactions contained 500 mM 
of each primer and diluted cDNA (25 ng except 2.5 ng for 18S).  For each tissue, data 
were analyzed using a relative standard curve generated using serial two-fold dilutions 
of cDNA prepared and pooled for the respective tissue.  Unknown sample expression 
was then determined from the standard curve.  18S expression was used as a covariate 
in the statistical analysis.   
GH induced insulin resistance 
To test whether Stat5 plays a role in GH induced insulin resistance, 18 week 
old WT and Stat5N male mice (n = 5-7 per genotype) were used in a cross-over 
design with 3.5 d periods separated by a 2 wk interval.  Treatments were twice daily 
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Table 3.1.  Real time PCR primers.
Gene1 Primer2 Sequence3
IGF-I F CAG TTC GTG TGT GGA CCG AG
R GCT CCG GAA GCA ACA CTC AT
PI3K F TCA TCA GTG TTG GCT TAC GCT 
R TTG TTG GCT ACA GTA GTG GGC 
18S F GTG GGC CTG CGG CTT AAT
R GCC AGA GTC TCG TTC GTT ATC
2F, forward; R, reverse.
3Primer sequences are shown in the 5’ to 3’ orientation.
1Primers were designed to measure the abundance of the acid labile subunit 
(ALS), insulin-like growth factor I (IGF-I), the p85a regulatory subunit of 
phosphotidylinositol 3-kinase (PI3K), and 18S ribosomal RNA (18S) 
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subcutaneous injections of saline or recombinant bovine GH (GH, 3 g/g 
BW/injection).  After the final injection at 0900h, feed was removed and an insulin 
tolerance test (ITT) was performed 6 h later.  Blood samples were obtained by nicking 
the dorsal tail artery.  The time 0 blood sample was taken followed by an 
intraperitoneal injection of human insulin (0.6 U/kg BW, Humulin® R, Eli Lilly and 
Company, Indianapolis, IN).  Blood was collected 30, 60, and 90 min after insulin 
injection.  Glucose measurements were performed with an Ascensia Contour 
glucometer (Bayer Health Care, Tarrytwon, NY).   
The response area to insulin was calculated from the time of challenge to 90 
min post-challenge. Response areas were calculated as percent drop from baseline 
(time 0 = 100%).  Area under the response curve was calculated using cubic spline 
interpolation and the trapezoidal rule with the EXPAND procedure in SAS (SAS 
Institute, Cary NC).   
Statistical analyses 
Analyses were performed using SAS statistical software (SAS Institute, Cary, 
NC).  For growth data (weight gain, lengths, and organ weights), data were separated 
by sex to avoid a 3-way interaction (sex x genotype x treatment).  Data were analyzed 
using the MIXED procedure of SAS (SAS Institute) for body weight, length, and 
organ data.  The model included fixed effects of covariate (initial body weight), 
genotype, treatment, and the interaction of genotype and treatment.  For all other data, 
the model included genotype, treatment, and the interaction of genotype and treatment.  
For analysis of real-time PCR data, the 18S value was used as the covariate.  For all 
analyses, the effect of genotype (Geno) was assessed by comparing saline-treated WT 
and Stat5N mice.  The interaction of genotype and treatment (Geno x Trt) was used to 
determine whether GH effects varied across genotype.  Statistical significance was set 
to P<0.05 for main effects and P<0.10 for the interaction.   
45
RESULTS 
Expression and activation of truncated Stat5 
Presence of truncated Stat5 has been evaluated in liver, but not in muscle or 
adipose tissue (Engblom et al. 2007).  First, we surveyed liver, adipose tissue, and 
muscle for expression of truncated Stat5 protein and determined if Stat5N could be 
activated by GH.  Male mice were treated with a single injection of GH and sacrificed 
15 minutes later.  Total and phospho-Stat5 were measured by Western blot in liver, 
gastrocnemius muscle and gonadal adipose tissue.  In WT mice, Stat5 was easily 
detected in all three tissues and was robustly phosphorylated in response to GH 
(Figure 3.1).   In Stat5N mice, truncated Stat5 was present in all three tissues but its 
abundance was substantially less than WT in liver and adipose tissue.  GH was able to 
activate Stat5N in all three tissues.   
Effect of GH treatment on body weight gain, linear growth, and organ weights 
In order to assess the role of Stat5 in GH-stimulated growth, we treated WT 
and Stat5N mice with exogenous GH for four weeks starting at d35 of age.  Body 
weights were recorded daily and cumulative weight gain calculated by difference from 
body weight at d35.  At the start of treatment, female and male Stat5N weighed 25% 
and 32% less than their WT counterparts (Stat5N vs. WT female, 13.0 vs. 17.4g; 
Stat5N vs. WT male, 14.8 vs. 21.7g, P<0.05).  The body weight gain curves show that 
female Stat5N and WT mice had similar growth patterns over the treatment period.  
Nevertheless, by the end of treatment, saline-treated Stat5N mice grew less than their 
WT counterparts (Figure 3.2C; Geno, P<0.05).   
The body weight gain curve of the saline-treated Stat5N males was obviously 
less steep than their WT counterparts.  In fact, their body weight gain curve was nearly 
super-imposable over that of saline-treated WT and Stat5N females (Figures 3.2A & 
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Figure 3.1.  Effect of acute GH treatment on activation of Stat5 protein in wild 
type and Stat5a/b N-terminal deletion mutant (Stat5N) mice.  Male wild type 
(WT) and Stat5N mice were treated with GH (GH, 4 µg/g BW) or an equivalent 
volume of saline (saline) (n = 3-5 for each genotype by treatment combination).  Mice 
were sacrificed 15 minutes after injection.  Protein extracts were prepared from liver, 
gastrocnemius muscle, and gonadal adipose tissue and analyzed by Western 



































Figure 3.2.  Effect of chronic GH treatment on body weight gain in female wild 
type and Stat5a/b N-terminal deletion mutant (Stat5N) mice.  Female wild type 
(WT) and Stat5N mice were treated twice daily with GH (GH, 3 µg/g BW/injection) 
or an equivalent volume of saline (saline) from day 35 to 63 of age.  Body weights 
were recorded daily throughout the treatment period.  A:  Weight gain was calculated 
for each day as the difference from body weight at the start of treatment.  B:  Weight 
gain achieved over the first week of treatment.  C:  Weight gain achieved over the 
entire treatment period.  Each line or bar represents the average of 6-8 mice.  The 
significant effects of genotype (Geno) and the interaction between genotype and 













































































Geno x Trt, 
P<0.01
Geno, P<0.05           




3.3A).  Accordingly, body weight gain in Stat5N males over the whole period was 
substantially less than saline-treated WT mice (Figure 3.3C; Geno, P<0.05). 
GH increased the gain of female WT mice by 210% after 1 week and by 130% 
over the entire treatment period, but these positive effects were completely absent in 
Stat5N females (Figures 3.2B & 3.2C; Geno x Trt, P<0.01 or less).  GH appeared 
somewhat less effective in stimulating body weight gain in WT males (compare 
Figure 3.2C to 3.3C), but again, its positive effects were not observed in Stat5N males 
(Figures 3.3B & 3.3C, Geno x Trt, P<0.07 or less).    
Body length measurements were taken at the end of treatment.  Body and 
femoral length were both decreased in male and female Stat5N mice (Figures 3.4A & 
3.4B; Geno, P<0.001 or less).  GH increased body length in WT mice but had no 
effect in Stat5N mice, irrespective of sex (Figures 3.4A & 3.4B; Geno x Trt, P<0.06 
or less).  A similar effect of GH on femoral length was also seen (Figure 3.4B; Geno x 
Trt, P0.05).   
Organ weights were measured at the end of the study (Tables 3.2 & 3.3).  The 
absolute organ weights of WT mice were significantly greater than those of Stat5N 
mice (Geno, P<0.05 or less).  These results were consistent between both sexes except 
that the liver weights were similar in female WT and Stat5N mice.  With the 
exception of muscle, GH treatment increased absolute organ weight of all tissues in 
WT but not in Stat5N mice (Geno x Trt, P<0.07 or less).   
Because of the significant differences in final body weight among the 
treatment groups, organ weights were normalized to final body weight.  Stat5N mice 
had heavier livers than WT mice but had lighter muscles (Tables 3.2 &3.3; Geno, 
P<0.05 or less).  Stat5N mice also tended to have a lighter gonadal fat depot (P<0.09 
or less). The genotype x treatment interactions occurred only in male muscle 
(increased only in WT, P<0.03) and female gonadal fat (reduced only in WT, P<0.08).   
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 Figure 3.3.  Effect of chronic GH treatment on body weight gain in male wild 
type and Stat5a/b N-terminal deletion mutant (Stat5N) mice.  Male wild type 
(WT) and Stat5N mice were treated twice daily with GH (GH, 3 µg/g BW/injection) 
or an equivalent volume of saline (saline) from day 35 to 63 of age.  Body weights 
were recorded daily throughout the treatment period.  A:  Weight gain was calculated 
for each day as the difference from body weight at the start of treatment.  B:  Weight 
gain achieved over the first week of treatment.  C:  Weight gain achieved over the 
entire treatment period.  Each line or bar represents the average of 6-8 mice.  The 
significant effects of genotype (Geno) and the interaction between genotype and 












































































Geno x Trt, 
P<0.07
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 Figure 3.4.  Effect of chronic GH treatment on cumulative body length and 
femoral length in wild type and Stat5a/b N-terminal deletion mutant (Stat5N) 
mice. Wild type (WT) and Stat5N mice were treated twice daily with GH (GH, 3 µg/g 
BW/injection) or an equivalent volume of saline (saline) from 35 to 63 d of age.  A:  
Body length (nose to anus) measurements taken at the end of treatment are shown for 
male and female mice.  B:  Femoral length measurements taken at the end of treatment 
are shown for male and female mice Each bar represents the mean ± SE of 6-8 mice.  
The significant effects of genotype (Geno) and the interaction between genotype and 
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Effect of GH treatment on indices of IGF-I expression 
Circulating IGF-I levels tended to be reduced in male Stat5N by 29% and were 
significantly reduced by 34% in female Stat5N (Figure 3.5; Geno, P<0.001).  GH 
treatment increased IGF-I levels by 73% and 88% in male and female WT mice, 
respectively but was completely ineffective at increasing circulating levels in Stat5N 
mice (Figure 3.5; Geno x Trt, P<0.05 or less).   
Liver is the predominant source of circulating IGF-I, and changes in plasma 
IGF-I are generally accounted by changes in hepatic IGF-I expression (Le Roith et al. 
2001).  To determine if this mechanism accounted for lack of GH-stimulated plasma 
IGF-I, IGF-I expression was analyzed in liver.  Given that the lack of GH effect was 
seen in both sexes and that the effect of Stat5N was more pronounced in males, this 
was done only in male mice.  Expression of the 7.5 kb IGF-I transcript was decreased 
65% in Stat5N male mice (Figure 3.6A; Geno, P<0.001).  GH treatment increased the 
expression of the 7.5 kb IGF-I transcript in WT liver but had no effect in Stat5N liver 
(Figure 3.6A; Geno x Trt, P<0.05).     
We also assessed hepatic expression of the ALS gene.  Like IGF-I, ALS is 
produced predominantly in liver in a GH-dependent manner. Stat5N mice expressed 
lower levels of the ALS transcript as compared to saline-treated WT (Figure 3.6B; 
Geno P<0.01).  Hepatic ALS expression increased in response to GH treatment in WT 
mice only (Figure 3.6B; Geno x Trt, P<0.05). 
Finally, we asked whether GH induction of IGF-I expression was also 
impaired in extra-hepatic tissues of Stat5N.  The Stat5N mutation decreased IGF-I 
expression in the muscle and the gonadal fat pad (Figure 3.7, Geno, P<0.05 or less).  
GH treatment increased expression of IGF-I in the gastrocnemius muscle and gonadal 
fat pad of WT male mice, but had absolutely no effect in Stat5N mice (Figure 3.7, 
Geno x Trt, P<0.05 or less).   
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 Figure 3.5.  Effect of chronic GH treatment on plasma IGF-I in wild type and 
Stat5a/b N-terminal deletion mutant (Stat5N) mice. Wild type (WT) and Stat5N 
mice were treated twice daily with GH (GH, 3 µg/g BW/injection) or an equivalent 
volume of saline (saline) from 35 to 63 d of age. Plasma was obtained on the last day 
of treatment and analyzed for IGF-I by RIA. Circulating IGF-I levels are shown for 
male and female mice.  Each bar represents the mean ± SE of 5 mice.  The significant 
effects of genotype (Geno) and the interaction between genotype and treatment (Geno 













































Geno x Trt, P<0.05 Geno, P<0.001           
Geno x Trt, P<0.0001
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 Figure 3.6.  Effect of chronic GH treatment on hepatic IGF-I and ALS mRNA in 
wild type and Stat5a/b N-terminal deletion mutant (Stat5N) mice. Wild type (WT) 
and Stat5N mice were treated twice daily with GH (GH, 3 µg/g BW/injection) or an 
equivalent volume of saline (saline) from 35 to 63 d of age.  Total RNA was isolated 
from liver of male mice and analyzed by Northern blotting for expression of IGF-I, 
ALS, and 18S.  A.  Left: Northern blot analysis of IGF-I gene expression.  Right:  
Each bar represents the mean ± SE (n=5) of the 7.5 kb IGF-I signal (normalized to 
18S).  The significant effects of genotype (Geno) and the interaction between 
genotype and treatment (Geno x Trt) are reported.  B.  Left:  Northern blot analysis of 
ALS gene expression.  Right:  Each bar represents the mean ± SE (n=5) of the ALS 
signal (normalized to 18S).  The significant effects of genotype (Geno) and the 
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 Figure 3.7.  Effect of chronic GH treatment on IGF-I mRNA expression in muscle 
and adipose tissue in wild type and Stat5a/b N-terminal deletion mutant (Stat5N) 
mice. Wild type (WT) Stat5N mice were treated twice daily with GH (GH, 3 µg/g 
BW/injection) or an equivalent volume of saline (saline) from 35 to 63 d of age.  Total 
RNA was isolated from the gastrocnemius muscle and gonadal adipose tissue of male 
mice.  IGF-I mRNA abundance was measured using quantitative real time PCR.  Each 
bar represents the mean ± SE of 6-8 mice.  The significant effects of genotype (Geno) 
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Geno, P<0.05           
Geno x Trt, P<0.01
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Effect of GH treatment on carbohydrate metabolism 
Chronic elevation of GH leads to insulin resistance (Dominici et al. 1999b), 
but whether this effect of GH requires Stat5 is unknown.  As an initial step to examine 
this issue, plasma was obtained at the end of the treatment period and analyzed for 
glucose and insulin.  In female mice, genotype did not affect plasma glucose or insulin 
(Table 3.4).  In male mice, plasma glucose was also similar between genotypes, but 
genotype impacted insulin levels.  Stat5N males had lower plasma insulin levels than 
their WT counterparts (Table 3.4, Geno, P<0.01).  
To assess more directly the role of Stat5 in GH-induced insulin resistance, 
insulin tolerance tests were performed on WT and Stat5N male mice.  At 30 minutes 
after insulin injection, blood glucose in WT saline-treated animals decreased ~30%, 
and a similar decline was seen in Stat5N mice, irrespective of treatment.  In GH-
treated WT mice, however, plasma glucose dropped only 15% (Figure 3.8A).  At 90 
minutes post insulin injection, plasma glucose levels were still suppressed in WT 
saline-treated and both saline- and GH-treated Stat5N mice while levels had returned 
to baseline in GH-treated WT mice (Figure 3.8A).  To quantify insulin responsiveness, 
area under the glucose response curve (AUC) was calculated and analyzed.  GH 
treatment significantly reduced AUC in WT mice but had no effect in Stat5N mice 
(Figure 3.8B; Geno x Trt, P<0.01).  Overall, these data demonstrate that GH induced 
insulin resistance in WT mice while GH-treated Stat5N mice remained insulin 
sensitive.   
GH-dependent insulin resistance has recently been linked to induction of the 
regulatory subunit of PI3K, p85 (Barbour et al. 2005).  This raises the possibility that 
GH is unable to induce p85 in Stat5N mice, and therefore may explain why these 
mice are more insulin responsive when treated with GH.   To evaluate this possibility, 











































































































































































































































































































































































































 Figure 3.8.  Effect of GH treatment on insulin sensitivity in wild type and 
Stat5a/b N-terminal deletion mutant (Stat5N) mice. Wild type (WT) Stat5N male 
mice were treated twice daily with GH (GH, 3 µg/g BW/injection) or an equivalent 
volume of saline (saline) for 3.5 days.  The basal concentration of blood glucose was 
measured at time 0, immediately before administration of insulin (0.6 mU/g BW).  
Blood glucose was measured again at 30, 60, and 90 minutes after insulin injection.  
A:  Response to insulin is expressed as percent of basal glucose.  Each point represents 
the mean ± SE of 5-6 mice.  B:  Area under the glucose response curve was calculated 
for each group using the trapezoid method.  Each bar represents the mean ± SE of 5-6 
mice.  The significant effects of genotype (Geno) and the interaction between 


































































of both WT and Stat5N male mice treated for a 4 week period with GH or saline.  
Basal levels of p85 expression were similar between saline treated WT and Stat5N 
male mice for all tissues (Figure 3.9, Geno, P>0.05).   In WT mice, exogenous GH 
increased or tended to increase p85 expression in liver, muscle, and gonadal fat but 
had no effect in Stat5N mice (Figure 3.9, Geno x Trt P=0.15 or less).   
DISCUSSION  
Studies performed over the last 15 years have characterized the molecular 
events involved in GH signaling and have identified the Stat5 proteins as central to its 
transcriptional effects (Hosui & Hennighausen 2008).  The Stat5 proteins consist of 
two isoforms, Stat5a and Stat5b, each encoded by its own gene (Liu et al. 1995).  
Genetic mouse models have been created in which each individual Stat5 gene has been 
ablated (Liu et al. 1997; Udy et al. 1997).  These models show that Stat5a is 
absolutely required for proper mammary gland development during late pregnancy 
and lactation, but Stat5a appears to play no role in growth (Liu et al. 1997).  On the 
other hand, Stat5b plays important roles in regulating sexually dimorphic growth rates 
and hepatic gene transcription (Udy et al. 1997).  Loss of Stat5b in male mice 
decreased body weight gain 27%, and knockout males grew at a rate similar to WT 
and Stat5b mutant females (Udy et al. 1997).   
In 1998, Teglund et al. (1998) attempted to knock out both Stat5a and Stat5b 
by inserting a neomyocin- and hygromyocin cassette into the first coding exon of the 
respective genes.  Their Stat5a mutant model had a similar phenotype as that described 
by Liu et al. (1997), with impaired mammary gland development but normal growth.  
Moreover, their Stat5b mutant model was characterized by a male specific deficit in 
postnatal growth similar to that described by Udy et al. (1997).  When both mutations 
were combined (Stat5N), male mice had a postnatal growth deficit similar to that 
reported in the original Stat5b mutant.  Interestingly, female Stat5N mice not only had 
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 Figure 3.9.  Effect of chronic GH treatment on p85 subunit of PI3K mRNA 
expression in liver, muscle, and adipose tissue in wild type and Stat5a/b N-
terminal deletion mutant (Stat5N) mice. Wild type (WT) and Stat5N mice were 
treated twice daily with GH (GH, 3 µg/g BW/injection) or an equivalent volume of 
saline (saline) from 35 to 63 d of age.  Total RNA was isolated from liver, 
gastrocnemius muscle, and the gonadal adipose tissue of male mice. And analyzed for 
mRNA abundance of the p85 isoform was measured by quantitative real time PCR.  
Each bar represents the mean ± SE of 6-8 mice.  The effects of genotype (Geno) and 
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Geno x Trt, P<0.01
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impaired mammary development but also suffered a growth deficit (Teglund et al. 
1998).   
Stat5N mice were believed to be true knockouts, but it has since been 
established that this strategy led to the synthesis of Stat5 proteins with N-terminal 
deletions (Riedlinger et al. 2002).  This is because the mutation strategy for both 
Stat5a and Stat5b targeted the naturally used start codon but left intact Kozak 
sequences and in-frame ATGs at amino acid position 103 and 137.  The ATG at 
position 137 is predominantly used in translation of the truncated proteins (Kornfeld et 
al. 2008).  Truncated Stat5 proteins were identified in liver of Stat5N mice (Engblom 
et al. 2007).  We now show that truncated Stat5 proteins are also present in muscle 
and gonadal adipose of Stat5N mice.  Truncated Stat5 proteins are significantly less 
abundant than Stat5 proteins in liver, muscle, and adipose tissue in WT mice but can 
be phosphorylated in response to GH. 
 Stat5N mice remain a valid model to study GH-dependent effects mediated by 
Stat5 even if they express truncated proteins.  First, total Stat5 ablation is not an option 
as shown by the perinatal lethality seen in total Stat5 knockouts (Cui et al. 2004).  
Second, the phosphorylated truncated Stat5 proteins are able to bind their cognate 
DNA element but are transcriptionally inactive for most Stat5-dependent growth-
related promoters in liver (Engblom et al. 2007).  The reason for this inactivity is that 
Stat5N proteins are lacking the N-terminal domain that is required for interaction with 
the glucocorticoid (GC) receptor, and this interaction is needed for transcriptional 
activation of most Stat5-dependent genes in liver (Engblom et al. 2007).     
Our study confirmed that Stat5N mice of both sexes grew at a slower rate than 
WT mice (Teglund et al. 1998; Engblom et al. 2007).  However, no studies have ever 
directly assessed whether growth effects of exogenous GH were also lost in Stat5 
deficient mice.  Chronic administration of GH has been used to evaluate the GH 
72
responsiveness of various GH/IGF-I mutant models (Liu & LeRoith 1999; Liu et al. 
2000b; Fielder et al. 1996).  GH responsiveness appears to be dependent on 
developmental stage.  Kasukawa et al. (2003) found that pubertal and post-pubertal, 
GH-deficient lit/lit mice treated with GH had greater body weight gain and increased 
circulating IGF-I levels as compared to those animals treated during the pre-pubertal 
period.  For these reasons, we treated WT and Stat5N mice with exogenous GH for 
four weeks between days 35 and 63 of age.  In response to exogenous GH treatment, 
WT male and female mice grew at a greater rate than their saline-treated counterparts; 
Stat5N mice, however, completely failed to respond to GH treatment. Similarly, GH 
treatment increased body and femoral length only in WT mice. 
The GH-IGF-I system is one of the major hormonal systems regulating 
postnatal growth.  After birth, approximately 35% of growth is mediated by the 
overlapping actions of GH and IGF-I (Lupu et al. 2001).  A portion of these actions 
represent GH-stimulation of endocrine IGF-I which is nearly completely liver-derived 
(Yakar et al. 1999).  The molecular mechanism whereby GH-dependent Stat5 
activation stimulates hepatic IGF-I transcription has only been elucidated recently.  
Three distinct GH response elements (GHRE) that contain paired Stat5b binding sites 
have been mapped within the rat IGF-I locus (Woelfle et al. 2003; Wang & Jiang 
2005).  More recently, five additional Stat5 binding sites, located in 3 new 
chromosomal regions, have been identified.  Individually, these regions are able to 
activate reporter gene expression via Stat5 binding, but a greater GH response is 
achieved when all five regions are present (Eleswarapu et al. 2008).  This mechanism 
has been confirmed in vivo.  In hypophysectomized rats infected with a control 
adenovirus, GH increased hepatic expression of IGF-I mRNA while infection with 
dominant-negative Stat5b adenovirus blocked IGF-I gene transcription.  In contrast, a 
constitutively-active Stat5b adenovirus stimulated IGF-I expression even in the 
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absence of GH (Woelfle et al. 2004).  These data illustrate that Stat5b is both 
necessary and sufficient for GH-induced expression of IGF-I in liver.  Our data 
confirm these observations because GH was completely unable to increase hepatic 
IGF-I mRNA and plasma IGF-I in Stat5N mice.  This also is consistent with data 
presented by Engblom et al. that glucocorticoid receptor interactions are critical for 
the ability of Stat5 to stimulate hepatic transcription of the IGF-I and ALS genes 
(Engblom et al. 2007). 
The second portion of the overlapping GH-IGF-I effects are carried out by the 
autocrine/paracrine IGF-I system and represent GH stimulation of extra-hepatic IGF-I 
synthesis (Mathews et al. 1986; Murphy et al. 1987).  Whether this stimulation was 
also dependent on Stat5 was unknown.  Thus, we evaluated basal and GH-stimulated 
IGF-I mRNA expression in muscle and adipose.  Similar to the pattern of hepatic IGF-
I mRNA expression, we showed that basal IGF-I expression levels in Stat5N mice are 
also decreased.  Consistent with this, muscle specific ablation of Stat5 decreased IGF-I 
mRNA expression in that tissue as well (Klover & Hennighausen 2007).  More 
specifically, we show that GH stimulated IGF-I expression in both tissues in WT mice 
while it failed to do so in Stat5N mice.  This finding also suggests that the interaction 
of GR and Stat5 is required for GH-stimulated IGF-I gene expression not only in liver, 
but also in extra-hepatic tissues.   
Excessive levels of GH alter organ growth proportionally for heart and spleen, 
but disproportionally increase the growth of liver and muscle (Le Roith et al. 2001).  
Indeed, we observed that exogenous GH induced a disproportional fractional liver 
growth in mice (Ueki 2006).  We intended to use these indices as a second measure of 
GH action in Stat5N mice.  The effect of GH on liver was of particular interest 
because liver has no IGF-I receptors (Werner et al. 1989), and thus could be used as 
an index of the growth effects of GH that are independent of IGF-I.  Lupu et al. (2001) 
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have shown that these IGF-I independent effects of GH account for ~14% of postnatal 
growth.  Overall, our results suggest that Stat5 is also required for GH effects that are 
independent of IGF-I.  Specifically, GH did not stimulate fractional liver weight and 
did not lead to a genotype x treatment interaction.  It is true that the fractional liver 
weight of Stat5N mice was increased.  Similar observations were made in null Stat5b 
and liver-specific null Stat5 mice (Udy et al. 1997; Cui et al. 2007).  As is the case for 
Stat5N, both of these models have lower plasma IGF-I and presumably excessive GH 
secretion.  However, failure of exogenous GH to stimulate fractional liver weight in 
WT mice suggests that liver hypertrophy in saline-treated Stat5N mice is not because 
of direct GH effects.   
The final GH-dependent endpoint we examined was insulin resistance.  
Chronic elevation of GH leads to hyperinsulinemia and insulin resistance (Dominici et 
al. 1999a).  Given that tissue specific Stat5 knockout models have altered glucose 
tolerance and insulin sensitivity, we evaluated the role of truncated Stat5 in GH-
induced insulin resistance.  Exogenous GH induced insulin resistance only in the WT 
mice while GH-treated Stat5N mice maintained normal insulin sensitivity.  These 
results suggest that GH-induced insulin resistant state is also dependent on a Stat5 
function. 
 Recent studies have identified a mechanism involving PI3K whereby GH 
antagonizes insulin signaling (Barbour et al. 2005).  PI3K is a heterodimer composed 
of the p85 subunit and the catalytic subunit p110.  The p85 subunit provides a binding 
domain for IRS proteins and regulates the activity of the p110 catalytic subunit 
(Dominici et al. 2005).  Increased expression of p85 increases the pool of free p85 
which competes with the p85-p110 heterodimer for binding sites on IRS-1.  As a 
result, PI3K activity decreases when free p85 is in excess (Biddinger & Kahn 2006).  
In muscle, GH-stimulated increase in p85 resulted in decreased PI3K activity and 
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subsequent insulin resistance (Biddinger & Kahn 2006).  Moreover, reduced p85 
expression prevented GH-induced insulin resistance (Barbour et al. 2005).  A similar 
mechanism of GH-stimulated p85 expression has been described in white adipose 
tissue (WAT) as well (Del Rincon et al. 2007).  Consistent with this mechanism, we 
showed that exogenous GH treatment in WT male mice stimulated p85 mRNA 
expression in liver, muscle, and gonadal fat.  More importantly, we show for the first 
time that Stat5 upregulated p85 expression in a GH-dependent manner because this 
effect was lost in liver, muscle, and fat of Stat5N mice.  Interestingly, another Stat 
protein, Stat3 regulates expression of the two other regulatory isoforms of PI3K, p50 
and p55 but has no effect on p85 (Abell et al. 2005).   
In conclusion, the N-terminal domain of Stat5 is absolutely necessary to 
mediate the effects of exogenous GH.  Stat5N mice fail to grow in response to GH 
treatment, likely due to the inability to stimulate IGF-I in liver and other tissues.  Lack 
of a GH effect on liver growth suggests that growth effects mediated by GH alone are 
also lost.  Finally, a functional Stat5 protein is required for GH-induced insulin 
resistance.   Stat5N mice remain insulin sensitive even when treated with exogenous 
GH, possibly due to the inability of GH to stimulate p85 expression.   
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CHAPTER FOUR: 




 The somatotropic axis plays an important role in growth and development (Le 
Roith et al. 2001).  Growth hormone (GH) can act directly on target tissues, or it can 
act by stimulating tissue production of insulin-like growth factor (IGF-I).  In the case 
of most tissues, IGF-I remains near its cellular site of production and represents the 
autocrine/paracrine arm of the IGF-I system (Le Roith et al. 2001).  These IGF-I 
molecules are usually bound to one of six IGF binding proteins (IGFBPs) (Jones & 
Clemmons 1995; Stewart & Rotwein 1996).  Liver-derived IGF-I, on the other hand, 
is secreted in plasma and represents the endocrine arm of the IGF-I system.  In 
postnatal animals, circulating IGF-I is bound in a 150 kDa ternary complex composed 
of one molecule each of IGF-I, IGFBP-3 or -5, and ALS (Baxter 1988; Twigg & 
Baxter 1998). 
ALS is thought to function exclusively as a component of the circulating IGF 
system.  It is responsible for formation of ternary complexes in circulation, building a 
reservoir of circulating IGF-I, and preventing its insulin-like effects (Zapf et al. 1995).  
Characterization of the null ALS mutant revealed a functional role for ALS in 
postnatal growth and metabolism (Ueki et al. 2000; Haluzik et al. 2003), but the role 
of ALS in mammary gland development has not been studied.   
The mammary gland undergoes extensive morphological and biochemical 
changes during postnatal life. These dynamic changes are under strict hormonal 
control by sex steroid hormones and various growth factors (Richert et al. 2000).  The 
most dramatic changes occur throughout four distinct stages:  virginity, pregnancy, 
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lactation, and involution.  During the first phase, the ducts elongate to fill the 
mammary fat pad (Hovey et al. 2002).  Development during pregnancy is 
characterized by further branching of the ducts and alveolar differentiation.  During 
lactation, the alveoli expand to completely fill the gland, and active milk secretion is 
established (Brisken 2002).  Upon weaning, the lactating gland undergoes involution 
where extensive remodeling of the gland returns it to pre-pregnancy form (Lamote et 
al. 2004).  GH, IGF-I, and IGFBPs are involved in mammary development through 
each of these stages.  A role for ALS, either through its ability to modulate plasma 
IGF-I or through local effects, has never been considered.  As an initial step to address 
this issue, we studied mammary gland development in null ALS mice.   
 MATERIALS AND METHODS 
Animals and experimental design 
Four studies were conducted to characterize ALS expression and its function 
during mouse mammary gland development.  Experimental procedures involving live 
animals were conducted with the approval of the Cornell University Institutional 
Animal Care and Use committee.  The facility was kept at constant temperature 
(~22C) and humidity (~65%) with controlled lighting (14 h light/10 h dark cycle).  
All animals were offered water and fed a standard rodent chow (Harlan Tekland 8640 
containing 22% protein, 5% fat, Harlan, Madison, WI) ad libitum. 
ALS expression during mammary gland development 
To determine the effect of physiological state on ALS expression in the 
mammary gland, age-matched FVB mice (d112) were studied when virgin, on d18 of 
pregnancy, d5 of lactation, or d2 of involution (n = 4-6/state).  Mice were euthanized 
by carbon dioxide asphyxiation.  Liver and the fourth mammary gland were dissected, 
snap-frozen immediately in liquid nitrogen, and stored at -80C for extraction of total 
RNA. 
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Role of ALS in pubertal mammary gland development 
Mammary development was studied in null ALS 12 mice or their WT 
counterparts.  Mice were of a mixed background (Balb/c x 129Sv), and experimental 
animals were generated by crossing heterozygous male and female mice.  For the 
study of virgin development, animals (n = 5-6 for each genotype by age combination) 
were sacrificed at 4, 6, and 8 wks of age.  Six and 8 week old animals were collected 
in diestrus as mammary structures are more uniform during that stage of the estrous 
cycle.  Stage of cycle was determined by evaluating vaginal smears stained with 0.1% 
methylene blue.  Mice were euthanized by carbon dioxide asphyxiation, and blood 
was collected by cardiac puncture, processed into plasma by the addition of heparin 
(60 U/mL) and stored at -20C.  The uterus was dissected and weighed.  The right, 
fourth mammary gland was fixed and embedded in paraffin while the contralateral 
gland was analyzed by whole mount staining.  
To determine whether lack of ALS delays age at puberty, 24d old WT and null 
ALS mice (n = 10/genotype) were housed with proven males.  Animals were checked 
daily for vaginal opening and presence of a copulatory plug.  Body weight was 
measured every other day.  Three days after observing a plug, animals were weighed 
and then euthanized by carbon dioxide asphyxiation.  Blood was collected 
immediately by cardiac puncture, processed to plasma by the addition of heparin 
(60U/mL) and stored at -20C.  The uterus was dissected and weighed.  Ovaries were 
dissected and copora lutea present at the surface of the ovary were counted using a 
dissecting microscope.  The right, fourth mammary gland was fixed and embedded in 
paraffin while the contralateral gland was analyzed by whole mount staining.  
Role of ALS in mammary development during pregnancy, lactation, and involution  
A total of 54 wild type and null ALS (Balb/c x 129Sv) female mice were 
studied during pregnancy, lactation, or involution (n = 3-6 animals/genotype at each 
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stage of development).  To obtain pregnant d8 and d18 animals, females were placed 
with proven males and evaluated daily for the presence of a copulatory plug, which 
represented d1 of pregnancy.  Pregnancy was confirmed at sacrifice.  To study 
development during lactation, the litter was normalized to 5-7 pups per dam on the day 
of parturition.  Dams were sacrificed on d2 or d10 of lactation (d1=day of parturition).    
A forced involution model was used to study mammary involution.  On the day 
of parturition, the litter was normalized to 5-7 pups per dam, and dams were allowed 
to lactate for 10 days before removing the pups.  Dams were euthanized 2, 4, or 6 days 
after pup removal by carbon dioxide asphyxiation.  The right, fourth mammary gland 
was fixed and embedded in paraffin while the contralateral gland was analyzed by 
whole mount staining.  
Role of ALS in GH-rescue of PRLR heterozygous mammary phenotype 
PRLR heterozygous (PRLR+/-) and WT (PRLR+/+) mice on a C57Bl/6 
background were obtained from The Jackson Laboratory (Bar Harbor, ME).  On this 
background, female PRLR-/- are infertile and PRLR+/- fail to lactate, the PRLR line 
was propagated by crossing WT females with PRLR+/- males.   
Experimental dams of interest were WT or null ALS mice harboring a single 
functional PRLR allele (i.e. ALS+/+/PRLR+/- or ALS-/-/PRLR+/-).  These animals 
were generated as followed.  First, PRLR+/- males were mated with WT or null ALS 
mice.  These mice originated from the ALS 12 line backcrossed for 5 generations onto 
a C57Bl/6 background.  F1 males of interested were recovered (either 
ALS+/+/PRLR+/- or ALS+/-/PRLR+/-).  ALS+/+/PRLR+/- males were crossed to WT 
ALS mice to generate WT ALS females harboring one or two functional PRLR 
allele(s).  ALS+/-/PRLR+/- males were crossed to null ALS mice to generate null ALS 
mice harboring one or two functional PRLR allele(s).   
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Seventy-two female mice were placed with proven male mice (n=10-16 for 
each of the four genotypes), and checked daily for presence of copulatory plug. The 
day a plug was observed was considered pregnancy d1.  A first subset of mice (n = 6-8 
for each of the four genotypes) was sacrificed at d14 of pregnancy.  A second subset 
of mice (n = 8-14 for each of the four genotypes) were also sacrificed.  WT or null 
ALS harboring one functional PRLR allele were randomly allocated to receive a daily 
subcutaneous injection of  the vehicle, 20% polyvinylpyrrolidone (PVP),  or 300 µg of 
bGH in 20% PVP (GH) on d14-17 of pregnancy (n = 6-8 for each genotype by 
treatment combination).  Animals were sacrificed at d18 of pregnancy.  To verify that 
loss of ALS does not influence mammary development in late pregnancy in this mouse 
strain, WT and null ALS mice harboring two functional PRLR alleles (n = 8 per 
genotype) were also sacrificed on d18 of pregnancy.  All animals were euthanized by 
carbon dioxide asphyxiation, and blood was collected by cardiac puncture, processed 
into plasma by the addition of heparin (60 U/mL), and stored at -20C.  The fifth 
mammary glands and liver were dissected, snap-frozen immediately in liquid nitrogen, 
and stored at -80C for extraction of total RNA.  The right, fourth mammary gland 
was fixed and embedded in paraffin while the contralateral gland was analyzed by 
whole mount staining.  
Genotyping analysis 
DNA was isolated from tail biopsies using the HotSHOT method (Truett et al. 
2000).  Briefly, tail biopsies (~4 mm) were incubated at 95C for 1 h in 100 L 
hydrolysis solution (25 mM NaOH, 0.2 mM EDTA, pH 12).  Samples were 
neutralized with an equal volume of 40 mM Tris-HCl, pH 5.0.  Genotyping was 
performed by PCR using 2 L of neutralized solution.  Final volume of the PCR 
reaction was 20 L and contained 1X Taq PCR buffer (10 mM Tris-HCl, 50 mM KCl, 
0.1% Triton x-100 and 1.0 mM MgCl2), 0.2 mM dNTPs and 0.625 units of Taq 
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polymerase (Promega, Madison, WI).  Primer sequences and expected product sizes 
are given in Table 4.1.  For ALS genotyping, final primer concentrations were 0.25 
M for F-Neo1 and F-ALS and 0.15 M for R-mPrB.  The reaction was first 
denatured at 95C for 5 minutes.  This was followed by 25 cycles of 94C for 30 
seconds, 60C for 30 seconds, and 72C for 1 minute with a 5 second extension per 
cycle.  A last cycle was performed identically except that the 72C step lasted 7 
minutes.  This combination of primers yielded bands of 602 bp for the WT ALS allele 
and 395 bp for the null ALS allele.  Products were visualized by agarose gel 
electrophoresis. 
For PRLR genotyping, final primer concentrations were 0.25 M for F-NeoP, 
0.6 M for F-PRLR, and 0.4 M for R-PRLR.    The reaction was first denatured at 
94C for 3 minutes.  This was followed by 34 cycles of 94C for 30 seconds, 67C for 
1 minute, and 72C for 1 minute.  A last cycle was performed identically except that 
the 72C lasted 2 minutes.  This combination of primers yielded bands of 537 bp for 
the WT PRLR allele and 400 bp for the null PRLR allele.  Products were visualized by 
agarose gel electrophoresis. 
Analysis of plasma IGF-I and estradiol 
Plasma IGF-I concentrations were measured using a rat IGF-I double antibody 
radioimmunoassay (RIA) purchased from Beckman Coulter (Webster, Texas).  
Analysis was performed as recommended by the manufacturer using 25 L plasma for 
acid-ethanol extraction.   
Plasma estradiol concentrations were measured using a RIA kit (Coat-A-Count 
Estradiol Kit, Siemens Medical Solutions Diagnostic, Malvern, PA).  The assay was 



































































































































































































































































































































RNA isolation and Northern analysis 
Total RNA from liver and mammary glands was extracted by affinity 
chromatography method as recommended by the manufacturer (RNeasy Mini Kit, 
Qiagen Inc., Valencia, CA).  The concentration of total RNA was determined by 
absorbance at 260 nm, and RNA quality was assessed on formaldehyde agarose gel by 
SYBR Green II staining (Molecular Probes, Eugene, OR). 
For Northern analysis, total RNA (10 g) was electrophoresed on a 1% 
denaturing agarose gel containing 0.66 M formaldehyde, 1X MOPS (0.04 M 3-N-
Morpholino-propanesulfonic acid, 0.05 M sodium acetate, 0.001 M EDTA, pH 8.0).  
Electrophoresis was performed for 2 h at 80 V in 1X MOPS.  Total RNA was 
transferred onto a nylon membrane (GeneScreenTM, NEN Research Products) by 
capillary transfer in 10X SSPE (1X SSPE = 0.18 M NaCl, 1 mM EDTA, pH 8.0; 1 
mM sodium phosphate).  Membranes were irradiated in a UV crosslinker at 120 
mJ/cm2, were dried for 1 h at 60C, and stored at -20C until hybridization. 
 To detect ALS mRNA, membranes were prehybridized at 50C in a solution of 
50% formamide/dextran sulfate, 5X SSPE, 10X Denhardt’s [1X Denhardt’s = 0.02% 
bovine serum albumin (BSA), 0.02% ficoll 400, 0.02% polyvinylpyrrolidone (MW 
40,000)], 100 mg/ml salmon sperm DNA, and 1% SDS.  The ALS probe used was a 
750 bp DNA fragment corresponding to nt +163 to nt +915 of the mouse ALS cDNA 
(numbering relative to A+1TG) (Ueki et al. 2000).  The probe was labeled with [-32P] 
dCTP (3000 Ci/mmol) by random priming (Prime-It, Stratagene, La Jolla, CA).  After 
a 2 h prehybridization, the DNA probe (~1 x 106 dpm/ml) was added and the 
hybridization continued overnight.  After hybridization, membranes were washed 
twice for 30 minutes in a solution of 2X SSPE/0.2% SDS at room temperature, and 
twice for 15 minutes in a solution of 0.1X SSPE at 60C.   
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The 18S ribosomal RNA was detected with a low specificity labeled 
oligonucleotide (Deindl 2001).  The oligo sequence is 5’-CGG AAC TAC GAC GGT 
ATC TG-3’ and was labeled with [-32P] dATP (3000 Ci/mmol) using T4 
polynucleotide kinase (Promega, Madison, WI).   Hybridizations were conducted at 
42C in a solution of 50% formamide/dextran sulfate, 5X SSPE, 10X Denhardt’s, 1% 
SDS.  Hybridizations were performed with the labeled probe (~2 x 106 dpm/ml) mixed 
with a 10-fold molar excess of unlabelled oligonucleotide.  Membranes were washed 
three times each with 2X SSPE/0.2% SDS at 45C.   
For visualization of ALS and 18S signals, membranes were exposed to x-ray 
film (Fuji Medical Systems USA, Inc., Stanford, CT).  Signals were quantified by 
phosphoimaging using a FUJIX BIO-IMAGING ANALYSER BAS1000 (Fuji Photo 
Film Co., Ltd.).   
Mammary gland whole mounts and histology 
 Whole mounts of mammary glands were performed as described by (Cui et al. 
2004).  First, individual mammary glands were spread onto a glass slide.  The glands 
were fixed overnight in Carnoy’s solution (60% ethanol, 30% chloroform, 10% acetic 
acid), post-fixed in 70% ethanol, rehydrated in a decreasing gradient of ethanol, and 
stained overnight in carmine-alum.  Slides were then dehydrated in an increasing 
ethanol gradient, cleared in xylene overnight, and coverslips were attached using 
Permount (Fisher Scientific, Pittsburg, PA).   
For histology, mammary tissues were fixed in 10% neutral buffered formalin 
overnight.  Tissues were embedded in paraffin, sectioned, and stained with 
hematoxylin and eosin (H&E).  Images of whole mounts were obtained using a 
dissecting microscope and digital camera.  Images of histological sections were 
captured using bright field microscopy. 
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 Ductal length was quantified by measuring the number of pixels between the 
center of the lymph node and the furthest extending duct.  An image of a ruler 
photographed under the same magnification was used to convert pixel number to mm.  
In this analysis, negative numbers are obtained when the ducts have not yet reached 
the node and the opposite when ducts have extended beyond the node. 
Immunohistochemistry 
Mammary glands were fixed in 10% neutral buffered formalin overnight at 
4C, embedded in paraffin, and sectioned.  The tissues were then dewaxed in xylene 
and rehydrated through a descending gradient of ethanol. Sections were incubated at 
95C for 20 min in 0.01M sodium citrate buffer (pH 6.0) for antigen retrieval. Tissues 
were permeabilized in 1X PBS +0.2% Triton X-100 for 20 minutes.  Slides were 
washed 3 times (3 minutes each) in 1X PBS +0.1% Triton X-100 and 3 times (3 
minutes each) in 1X PBS.  Sections were blocked at room temperature for 1 hr in 10% 
normal donkey serum +1% BSA in 1X PBS, pH 7.4.  Samples were first incubated 
with goat anti-mouse ALS (R&D Systems, Inc., Minneapolis, MN) diluted 1:500 in 
1X PBS +1% BSA overnight at 4°C.  Slides were washed as above then incubated 
with Cy3-conjugated donkey anti-goat antibody (Jackson ImmunoResearch 
Laboratories, Inc., West Grove, PA) diluted 1:500 in 1X PBS +1% BSA for 1 h at 
room temperature.  Slides were washed as above.  Nuclei were stained with 4´,6-
diamidino-2-phenylindole [DAPI (Sigma, St. Louis, MO)].  Tissue staining was 
documented using an Axiovert 40 microscope (Carl Zeiss, Inc., Thornwood, NY) 
equipped with an AxioCam camera (Carl Zeiss, Inc.). 
Statistical analyses 
Analyses were performed using SAS statistical software (SAS Institute, Cary, 
NC).  Data were analyzed using the MIXED procedure of SAS (SAS Institute).  For 
the ALS expression data, the model included the fixed effects of stage (Stage) and 
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tissue (Tissue), and their interaction (Stage x Tissue).  For the pubertal mammary 
development data, the model included the main effect of genotype (Geno).  For the 
plasma IGF-I data at pregnancy d14, the model included the fixed effects of PRLR 
genotype (PRLR) and ALS genotype (Geno) and their interaction.  At pregnancy d18, 
the model included the fixed effects of genotype (Geno) and treatment (Trt) and their 
interaction (Geno x Trt).  Statistical significance was set to P<0.05 for main effects 
and P<0.10 for the interaction.   
RESULTS 
Expression of ALS in the mammary gland throughout development 
In the mouse, we have detected ALS gene expression in the liver, gonadal fat, 
and kidney, and virgin mammary gland (Giesy 2004).  ALS expression has not been 
described throughout the different phases of mammary development in any species.  
To do this in the mouse, we obtained the mammary gland during the virgin state, on 
d18 of pregnancy, on d5 of lactation, and on d2 of involution.  At each developmental 
stage, mammary ALS expression was determined and compared to hepatic ALS 
expression.   
The relationship between liver and mammary expression in the virgin state was 
different than that in the pregnant, lactating or involuting state (Figure 4.1; Tissue x 
State, P<0.01).  Expression in the mammary gland was only 15% of that of liver in the 
virgin state (Tissue, P<0.001).  In all other states, however, mammary ALS expression 
increased substantially such that it was similar to hepatic expression.  Therefore, 
pregnancy, lactation, and involution are periods of high ALS expression in the 
mammary gland.   
Next, we attempted to identify the mammary compartment expressing ALS 
using immunohistochemistry.  During pregnancy, lactation, and involution, ALS 
immunoreactivity was detected within the ductal and/or alveolar lumens (Figure 4.2).  
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Figure 4.1.  Effect of physiological state on the expression of the ALS gene in liver 
and mammary gland.  FVB mice were sacrificed when virgin (112d of age) and on 
d18 of pregnancy, d5 of lactation, or 2 days after pup removal (involution).  Liver and 
the 4th mammary gland were collected.  Top:  Total RNA was isolated from tissues 
and analyzed by Northern blotting for expression of the ALS and 18S genes.  Samples 
from 3 representative females are shown.  Bottom:  Each bar represents the mean ± SE 
(n=4-6/state) of the ALS signal (normalized to 18S).  The effects of tissue (Tissue), 










































Stage, P<0.0001          
Stage x Tissue, P<0.01
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Figure 4.2.  Immunodetection of the ALS in the mammary gland.  Wild type (WT) 
and null ALS (Null) mice were sacrificed on d18 or pregnancy, d2 of lactation, or 2 
days after pup removal (involution). The 4th mammary gland was collected and 
analyzed for ALS protein by immunohistochemistry.  Photographs for ALS staining 
(red) and nuclei staining (blue) are shown individually or as a merged photograph.  
Glands from null ALS mice served as negative controls.  Representative photographs 















ALS immunoreactivity, however, was not visible in mammary epithelial cells as the 
signal did not localize in proximity of the stained nuclei.  The antibody was specific 
for ALS as no signal was observed in mammary glands from null ALS mice. 
Mammary development before and after puberty 
To determine if ALS is important for this phase of mammary development, 
mammary gland whole mounts were prepared from WT and null ALS mice at 4, 6, 
and 8 wk of age.  Ductal elongation was measured as the distance from the mammary 
lymph node.  At 4 weeks of age, ductal extension was comparable between WT and 
null ALS mice (Figure 4.3; Geno, P>0.10).  At 6 weeks of age, however, ductal 
extension was significantly less in null than WT mice (0.9 mm in null vs 4.4 mm in 
WT; Geno, P<0.05).  At 8 weeks of age, ductal elongation tended to be greater in WT 
than null ALS mice (Geno, P0.10).  These results indicate that mammary ductal 
elongation progresses at a slower rate in the absence of ALS. 
Body and uterine weights were also analyzed in these virgin animals (Table 
4.2).  As expected, null mice weighed significantly less than their WT counterparts at 
4 and 6 weeks of age (Geno, P<0.05 or less).  At 8 weeks of age, null mice tended to 
weigh less than WT mice (Geno, P<0.09).  Absolute uterine weights were 
significantly lower in null mice at 4 and 8 weeks of age (Table 4.2; Geno, P<0.05).  
When expressed as a percent of body weight, uterine weight was significantly lower in 
null mice only at 8 weeks of age (Geno, P<0.05).   
The mammary and uterine data suggested that some aspects of sexual 
maturation were proceeding more slowly in null ALS mice.  Ductal elongation 
depends on estrogen receptor (ER) signaling even before puberty.  To determine 
whether the slower rate of ductal extension is related to an estrogen deficit, we 
measured plasma estradiol levels at 4 and 6 weeks of age.  Plasma estrogen levels 
were significantly higher in null than in WT mice at both ages (Figure 4.4A; Geno, 
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Figure 4.3.  Mammary gland development in virgin wild type and null ALS mice.  
Top:  Wild type (WT) and null ALS (Null) mice at diestrus were sacrificed at 4, 6, and 
8 weeks of age (n = 5-6 for each genotype by treatment combination).  The 4th 
mammary gland was collected and analyzed by whole mount.  Representative images 
are shown.  Bottom:  Ductal length relative to the furthest duct was measured to the 
center of the lymph node.  Values are negative when ducts have not reached the node 
and positive when extended beyond.   Each bar represents the mean ± SE of 5-6 mice.  









































































































































































































































































































































































































Figure 4.4.  Plasma estrogen and IGF-I levels in virgin wild type and null ALS 
mice. Plasma was collected from wild type (WT) and null ALS (Null) mice and 
analyzed by radioimmunoassay for estrogen at 4 and 6 weeks of age (A) and IGF-I at 
4 weeks of age (B).  Each bar represents the mean ± SE of 6 mice.  The significant 
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P<0.01).  We also measured circulating IGF-I levels at 4 weeks of age.  Plasma IGF-I 
levels in ALS null mice were only 20% of wild type levels (Figure 4.4B; Geno, 
P<0.0001).   
  As a functional test for sexual maturation, we compared WT and null ALS 
mice for the timing of vaginal opening and presence of a copulatory plug when placed 
with a proven male starting at 24 d of age.  Age at vaginal opening was similar 
between null and WT mice (Table 4.3; Geno, P>0.10); however, age at plug tended to 
be greater in null mice (41.3 d vs 37.9 d, null vs WT; Geno, P<0.07).  As expected, 
ALS null mice weighed 15% less on day of plug (Table 4.3; Geno, P<0.01).   
All mice were sacrificed 3 days later to evaluate other indices affected by 
sexual maturation (Table 4.3).  There was no difference in absolute or percent uterine 
weight (Geno, P>0.10).  Interestingly, null females tended to have fewer corpora lutea 
(CL) than WT females at the surface of their ovaries (Geno, P<0.09), suggesting that 
they ovulated fewer eggs.  Finally, mammary ductal length was similar between WT 
and null ALS in this set of mice (Geno, P>0.10).  Overall, these data show that lack of 
ALS results in delayed ductal elongation during pubertal development.  In the 
presence of a male, null ALS animals tend to reach puberty at a slightly older age but 
show no impairment in ductal development by the time a plug is detected.   
Mammary development during pregnancy 
In order to determine the importance of ALS during pregnancy, mammary 
whole mounts were collected from WT and null ALS mice in early (d8) and late (d18) 
pregnancy.  Early pregnancy is a period of rapid ductal branching and alveolar bud 
formation.  These structures were readily observed in glands from WT mice but 
appeared less abundant in null ALS mice (Figure 4.5A).   
Late pregnancy is characterized by near complete invasion of the mammary fat 
































































































































































































































































































































































Figure 4.5.  Mammary gland development in wild type and null ALS mice during 
pregnancy.  Wild type (WT) and null ALS (Null) mice were sacrificed on d8 and d18 
of pregnancy (n =3 for each genotype x time combination), and the 4th mammary 
gland was collected.  A:  Whole mounts (WM) were prepared at each stage of 
pregnancy.  Representative images are shown.  Alveolar buds are marked with an 
arrowhead.  B:  On d18 of pregnancy, histological evaluation was performed with 
hematoxylin and eosin (H&E) staining, and slides were photographed at 2 levels of 
magnification (50X and 400X).  Representative images are shown.  Lipid droplets are 















alveolar structures.  This was seen equally well at d18 of pregnancy in both WT and 
null ALS mammary glands (Figure 4.5B, H&E 50X).  Moreover, both WT and null 
ALS mammary glands appeared similarly differentiated as shown by the presence of 
milk fat droplets within the alveolar epithelial cells and proteinacious material within 
the alveolar lumen (Figure 4.5B, H&E 400X).  These results suggest that ALS may 
promote early alveolar formation but is not essential for its completion by late 
pregnancy.   
Next we tested the role of ALS for mammary gland development in mice 
heterozygous for the PRLR (PRLR +/-).  These mice have a complete block in 
alveolar expansion starting on d14 of pregnancy.  Allan et al. (2002) showed that 
exogenous GH therapy rescued this defect and speculated that a GH-dependent 
increase in plasma IGF-I was involved.  GH, however, is unable to increase plasma 
IGF-I in null ALS mice (Ueki 2006).  These observations prompted us to ask whether 
GH could still rescue the mammary defect occurring in PRLR +/- mice in the absence 
of ALS.  WT and null ALS mice carrying a single functional PRLR allele were 
created.  To confirm that the alveolar expansion defect occurred in these mice, 
mammary development was examined by whole mount at pregnancy d18.  In mice 
carrying two functional PRLR alleles, mammary alveolar differentiation had occurred.  
The alveoli were filling the fat pad, and fat droplets were observed within the 
epithelial cells (Figure 4.6, H&E 400X).  Presence of a single PRLR allele was 
insufficient to support full alveolar expansion in mice.  This defect occurred to the 
same extent in null ALS mice (Figure 4.6, H&E 50X).   
Next, WT and null ALS mice carrying a single functional PRLR allele were 
treated with exogenous GH between d14-d17 of pregnancy.  At pregnancy d14, PRLR 
copy number did not impact plasma IGF-I, but absence of ALS reduced plasma IGF-I 
from 210 to 144 ng/mL (Figure 4.7A; Geno, P<0.05).  At pregnancy d18, GH 
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Figure 4.6.  Mammary gland development in wild type and ALS null mice 
carrying one or two functional copies of the PRLR gene during late pregnancy.  
Wild type (WT) and null ALS (Null) mice carrying two functional copies of the PRLR 
(PRLR +/+) or only one (PRLR +/-) were sacrificed on d18 of pregnancy (n = 6-9 per 
genotype).  The 4th mammary gland was collected and analyzed by whole mount 
(WM).  Histological evaluation was performed with hematoxylin and eosin (H&E) 
staining, and slides were photographed at 2 levels of magnification (50X and 400X).  










































Figure 4.7.  Effect of PRLR copy number and ALS genotype on plasma IGF-I.   
A: On d14 of pregnancy, plasma was collected from mice carrying two functional 
copies of the PRLR (PRLR +/+) or only one (PRLR +/-) and from wild type (WT) and 
null ALS (Null) mice.  Plasma was assayed for IGF-I by radioimmunoassay.  Each bar 
represents the mean ± SE of 5-6 mice.  The significant effect of the ALS genotype 
(Geno) is reported.  B: Wild type (ALS WT) and null ALS (Null) mice carrying one 
functional copy of the PRLR gene were treated once daily with GH (GH, 300 µg/day) 
or an equivalent volume of vehicle [20% polyvinylpyrrolidone (PVP)] from d14-17 of 
pregnancy.  Mice were sacrificed on d18 of pregnancy (n = 6-8 for each genotype by 
treatment combination).  Plasma was collected and analyzed for IGF-I by 
radioimmunoassay.  Each bar represents the mean ± SE of 5-6 mice.  The effects of 
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increased plasma IGF-I 25% in WT mice but had no effect in null ALS mice (Figure 
4.7B; Geno x Trt, P<0.05).  Unexpectedly, plasma IGF-I levels were not different 
between null ALS and WT vehicle-treated mice.  Mammary glands were also obtained 
at pregnancy d18 and examined by whole mount analysis.  Exogenous GH treatment 
stimulated alveolar expansion irrespective of absence or presence of ALS (Figure 4.8, 
WM).  This is illustrated by increased occupation of the fat pad by alveoli in GH 
treated animals. Irrespective of the ALS genotype, GH failed to induce the appearance 
of lipid droplets within the epithelial cells (Figure 4.8, H&E 400X).  These data show 
that the ability of GH to rescue the alveolar expansion defect in PRLR +/- occurs in 
the absence of any change in plasma IGF-I and is completely independent of ALS.   
Mammary development during lactation and involution 
A coordinated balance between IGF-I and IGFBPs is necessary for survival of 
the epithelial cell population during lactation.  To determine whether ALS may 
regulate this balance, mammary whole mounts were collected from WT and null ALS 
mice during lactation.  No discernible differences were detected between the whole 
mounts of WT and null mice at d2 and d10 of lactation (Figure 4.9, WM).  Histology 
of the gland appears to be normal in both genotypes with the alveoli expanding to 
completely fill the gland by d10 of lactation.  Therefore, ALS is not required for 
mammary development during lactation.   
Upon weaning, the lactating gland undergoes involution whereby extensive 
remodeling of the gland returns it to pre-pregnancy state.  The process of involution 
involves apoptosis of the mammary epithelial cells and structural remodeling of the 
gland, characterized by a loss of epithelia and reappearance of lipid-filled adipocytes 
(Richert et al. 2000).  This process is dependent on the induction of IGFBP-5 
synthesis within the mammary gland.  IGFBP-5 inactivates IGF-I to allow involution 
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Figure 4.8.  Effect of GH treatment on mammary gland development during late 
pregnancy in wild type and null ALS mice carrying one functional copy of the 
PRLR gene.  Wild type (ALS WT) and null ALS (Null) mice carrying one functional 
copy of the PRLR gene were treated once daily with GH (GH, 300 µg/day) or an 
equivalent volume of vehicle [20% polyvinylpyrrolidone (PVP)] from d14-17 of 
pregnancy (n = 6-8 for each genotype by treatment combination).  Mice were 
sacrificed on d18 of pregnancy and the 4th mammary gland was collected and analyzed 
by whole mount (WM). Histological evaluation of mammary tissue sections was 
performed with hematoxylin and eosin (H&E) staining, and slides were photographed 










































Figure 4.9.  Mammary gland development in wild type and null ALS mice during 
lactation.  Wild type (WT) and null ALS (Null) were sacrificed on d2 or d10 of 
lactation (n = 3-6 for each genotype x time combination).  The 4th mammary gland 
was collected and analyzed by whole mount (WM).  Histological evaluation was 
performed with hematoxylin and eosin (H&E) staining, and slides were photographed 








































to proceed (Flint et al. 2008).  Since ALS is capable of binding binary IGF-I:IGFBP-5 
complexes, we evaluated the progression of involution in null ALS and WT mice.   
On d2 of involution, mammary gland morphology was similar between WT 
and null ALS mice.  Epithelial cells occupy the majority of the gland and alveoli are 
intact (Figure 4.10, H&E 50X).  By d4, involution appears to be delayed in null ALS 
mice.  A greater proportion of epithelia still populates the emerging fat pad (Figure 
4.10, H&E 50X) and a greater number of alveoli are intact in null ALS mice (Figure 
4.10, H&E 400X).  Involution is still delayed in null ALS mice at d6.  In WT animals, 
the alveoli have collapsed while alveolar structures are still present in null ALS mice 
(Figure 4.10, H&E 400X).  These data suggest that loss of ALS in the mammary gland 
delays the process of involution.    
DISCUSSION 
 So far, ALS has been postulated to function exclusively as a component of the 
circulating IGF-I system.  It is responsible for formation of ternary complexes and the 
development of the circulating IGF-I reservoir (Boisclair et al. 2001).  Consistent with 
this, plasma levels of IGF-I and IGFBP-3 are reduced by 62% and 88%, respectively 
in null ALS mice (Ueki et al. 2000).  Additional studies have established that IGF-I 
deficiency associated with lack of ALS had functional impacts.  First, null ALS mice 
suffer a 13-20% growth deficit after birth (Ueki et al. 2000).  Bone length is shorter 
and bone metabolism is impaired in null ALS mice (Yakar et al. 2002).  Null ALS 
mice have normal plasma glucose and insulin concentrations (Ueki et al. 2000) but are 
protected from GH-mediated insulin resistance (Haluzik et al. 2003; Ueki 2006).  The 
mammary gland is highly dependent on the GH-IGF-I system, but the functional role 
of ALS in mammary development has not been studied.   
 As an initial step to assess the role of ALS in mammary gland development, 
we compared mammary gland whole mounts from WT and null ALS mice during the 
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Figure 4.10.  Mammary gland development in wild type and null ALS mice 
during involution.  Wild type (WT) and null ALS (Null) were sacrificed on d2, d4, or 
d6 after pup removal (involution; n = 3-4 for each genotype x time combination).  The 
4th mammary gland was collected and analyzed by whole mount (WM).  Histological 
evaluation was performed with hematoxylin and eosin (H&E) staining, and slides 
were photographed at two levels of magnification (50X and 400X).  Representative 
images are shown.  Collapsed alveolar structures are marked with an arrowhead, and 



















































period of ductal elongation, and during pregnancy, lactation, and involution.  This 
survey suggested that absence of ALS leads to three specific mammary defects 
namely, delayed ductal elongation, impaired ductal branching and alveolar budding in 
early pregnancy, and delayed involution.  Development during late pregnancy and 
lactation, on the other hand, appeared completely normal in null ALS mice.   
Our study, however, has two significant limitations.  First, we found 
significant ALS expression in the mammary gland at all stages examined.  This 
observation is not a complete surprise as low levels of ALS mRNA expression have 
been detected in extra-hepatic tissues of a variety of species. For instance, low levels 
of ALS mRNA were detected in the rat renal cortex by in situ hybridization (Chin et 
al. 1994), in pig muscle, spleen, ovary and uterus by ribonuclease protection assay 
(RPA) (Lee et al. 2001), and in cow lung, small intestine, adipose, kidney and heart by 
RPA (Kim et al. 2006).  More recently, we have reported significant levels of ALS 
expression in mouse adipose tissue and kidney (Giesy 2004).  The level of ALS 
expression in the mammary gland during pregnancy, lactation, and involution is 
unusual in that it matches hepatic expression.  We are not aware of any other non-
hepatic tissue where this is the case.     This observation, however, means that we are 
unable to attribute exclusively any of the defects identified in null ALS mice entirely 
to absence of ALS in plasma.  
The second limitation is that the mammary gland is a heterogeneous tissue 
composed of epithelia, adipocytes, and connective tissue (Watson & Khaled 2008).  
The proportion of these compartments varies significantly throughout the different 
developmental stages (Richert et al. 2000).  Any single one of these tissue 
compartments could express ALS.  To address this issue, we tried to localize ALS 
protein by immunohistochemistry.  ALS protein was detected in the lumen of the 
ducts and/or alveoli, but we were unable to visualize ALS protein within the epithelial 
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cells or adipocytes.  At this time, we do not know exactly which cell types express 
ALS throughout the various stages of mammary development.  Nevertheless, given 
what is known about the composition of the gland during development, some general 
statements are appropriate.   First, mammary adipose tissue is likely a site of 
significant ALS expression during the period of pubertal development and early 
pregnancy.  This is because adipose tissue accounts for more than 70% of the tissue at 
these times (Silberstein 2001) and because we previously showed that non-mammary 
adipose tissue expresses ALS at ~52% of the levels seen in liver (Giesy 2004).  In 
contrast, epithelial cells occupy most of the mammary gland during late pregnancy and 
throughout lactation and involution (Richert et al. 2000), and thus must synthesize 
some ALS at these stages.  However, we cannot exclude contribution by the 
epithelium during pubertal development or contribution by remaining adipocytes at 
later stages.  
 Despite these limitations, it is still relevant to put our findings in the context of 
roles played by the GH-IGF-I system in regulating mammary development, with 
respect to ductal growth.  Ruan et al. (1992) demonstrated that IGF-I can substitute for 
GH mediated ductal growth in hypophysectomized rats.  Estrogen also plays a role in 
ductal elongation.  In mice lacking estrogen receptor  (ER), no ductal development 
occurs (Mallepell et al. 2006).  Moreover, estrogen enhances GH-induced expression 
of IGF-I mRNA in the mammary fat pad and synergizes with IGF-I to stimulate ductal 
growth (Ruan et al. 1995).  Our data also show that sexual maturation, assessed by 
presence of a copulatory plug, proceeds more slowly in null ALS mice.  However, 
neither defect appears related to a deficit in estradiol as null ALS mice had higher 
plasma estradiol levels.   
 It is possible that the plasma IGF-I deficit of null ALS mice is responsible for 
the delay in ductal elongation.  Few studies have assessed the role of circulating IGF-I 
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in pubertal mammary development.  In one study, pubertal development was studied 
in the hypomorphic IGF-Im/m model (Richards et al. 2004).  In these mice, the IGF-I 
allele contains a site-specific intronic insertion of the targeting construct which results 
in a 70% reduction in circulating IGF-I and ~50% reduction in mammary IGF-I 
mRNA (Richards et al. 2004).  Ductal elongation was delayed and branching 
complexity was impaired in IGF-Im/m females (Richards et al. 2004).  The authors 
attribute this developmental defect to a decrease in local IGF-I production as 
branching complexity was normal in the liver-specific IGF-I deficient (LID) females, 
which have a 75% decrease in circulating IGF-I.  However, mammary gland 
development was only analyzed in 90d old mice, and this design would not detect 
early defects that are normalized over time such as the one we saw in null ALS mice.   
 IGF-I is also important in early pregnancy, promoting proliferation of ductal 
branches and formation of alveolar buds (Richert et al. 2000).  This was shown in 
female mice lacking one copy of the IGF-I gene, which have impaired alveolar 
budding at d5.5 of pregnancy (Loladze et al. 2006).  Similarly, we show a significant 
decrease in alveolar budding in null ALS mice at d8 of pregnancy.  The null ALS mice 
have normal IGF-I expression in all tissues examined so far (Ueki et al. 2000), and 
accordingly, are also expected to have normal mammary IGF-I expression.  If this is 
the case, this would leave the plasma IGF-I deficit as the common feature in both 
models. 
 In an attempt to further study the role of ALS during pregnancy, we created 
WT or null ALS mice harboring a single functional PRLR allele.  Ormandy et al. 
(1997) previously showed that mice harboring a single PRLR allele have normal 
mammary gland development until d14 of pregnancy, but then suffer for a near 
complete arrest of lobulo-alveolar expansion.  This defect can be rescued by 
exogenous GH treatment starting at d14 of pregnancy (Allan et al. 2002).  This rescue 
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was associated with a 2.5-fold increase in plasma IGF-I on d2 of lactation, raising the 
possibility that elevated plasma IGF-I was responsible.  Our data, however, show that 
GH induced lobulo-alveolar expansion equally well in null ALS mice carrying one 
copy of the PRLR gene, demonstrating that effects of GH are mediated by local effects 
on the mammary gland and not by endocrine IGF-I.   
 Finally, we observed a delayed progression of involution in the mammary 
gland of ALS null mice.  It is well established that IGF-I acts as a survival factor for 
the mammary epithelial cell (Green & Streuli 2004).  Thus, over-expression of IGF-I 
in the mammary glands of lactating mice delays the involution process 
(Neuenschwander et al. 1996).  Moreover, involution is associated with mammary-
specific induction of IGFBP-5 (Tonner et al. 1997), which can then neutralize IGF-I 
and its pro-survival effects (Tonner et al. 2002).  Consistent with this role, appearance 
of apoptotic cells and the reappearance of adipocytes were both retarded in IGFBP-5 
null mice during involution (Ning et al. 2007).  This is quite similar to the defect we 
saw in null ALS mice.  This defect appears more likely to relate to local rather than 
systemic ALS effects.  First, if systemic IGF-I did play a role in involution, then one 
would expect that the lower levels of circulating IGF-I in null ALS mice would 
accelerate rather than delay mammary involution.  Second, locally produced IGFBP-5 
neutralizes IGF-I induced proliferation during involution, and ALS is known to form 
ternary complexes by interacting with IGF-I/IGFBP-5 complexes (Twigg & Baxter 
1998).  It is tempting to speculate that locally-derived ALS binds IGF-I/IGFBP-5 
complexes during involution, and in this manner, increases the neutralization effects of 
IGFBP-5.   
 In summary, we have shown that null ALS mice have reduced ductal 
elongation in the virgin state as well as reduced branching and alveolar budding in 
early pregnancy.  Moreover, involution is delayed in null ALS mice.  We detect ALS 
118
mRNA expression and presence of the protein in the mammary gland.  In order to 
understand the mechanism of action of ALS, it is now essential to identify which cell 
type expresses ALS at each stage of mammary development.  This is the first step 
before specific approaches, such as cell specific ablation of ALS expression, can be 
considered to address whether the defects arise from plasma or locally produced ALS.  
Cell specific gene ablation in the mammary gland, particularly at specific stages of 
development, is not currently feasible.   A more realistic approach at this time may be 
the development of a liver-specific ALS knockout.  In this model, any remaining 
mammary defects could be attributed to the effects of ALS on the circulating IGF-I 
system.   
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CHAPTER FIVE: 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 Growth hormone (GH) can act directly on target tissues, or it can act indirectly 
by stimulating insulin-like growth factor (IGF-I) production (Le Roith et al. 2001).  
IGF-I can act either in an autocrine/paracrine fashion via locally produced IGF-I or in 
an endocrine fashion through circulating IGF-I (Le Roith et al. 2001).  In plasma, ALS 
associates with IGF-I in a ternary complex and is responsible for development of the 
endocrine pool of IGF-I.  GH regulation of postnatal growth and liver-derived IGF-I is 
mediated via the signaling intermediate, Stat5 (Waters et al. 2006; Woelfle & Rotwein 
2004).   
Our first objective was to test whether exogenous GH could stimulate growth, 
development, and insulin resistance in Stat5 mutant mice.  Upon initiation of this 
work, three independent Stat5 mouse mutants had been created, null Stat5a (Liu et al. 
1997), null Stat5b (Udy et al. 1997), and a mutant thought to combine null Stat5a and 
5b alleles (Stat5N) (Teglund et al. 1998).  These models demonstrated that Stat5a is 
involved in mammary development (Liu et al. 1997), and Stat5b is involved in hepatic 
gene regulation and postnatal growth (Udy et al. 1997).  As expected, the Stat5N mice 
combined all the defects seen in the individual mutants (Teglund et al. 1998).  These 
mice were believed to be true knockouts, but it has since been shown that they express 
hypomorphic N-terminally deleted Stat5 proteins.  Presence of truncated Stat5 proteins 
has been described in liver (Engblom et al. 2007).  We show that muscle and adipose 
tissue also express the truncated proteins.  Abundance of the truncated Stat5 proteins 
in Stat5N tissues was less than that of Stat5 in WT tissues.  Nevertheless, GH was 
able to activate the truncated Stat5 proteins in all tissues.   
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Previous studies showed that postnatal growth is impaired in Stat5N mice 
(Teglund et al. 1998), but whether all effects of GH are lost is unknown.  More 
recently, total Stat5 knockouts were created by ablating the entire Stat5 locus.  Total 
loss of both Stat5 isoforms, however, resulted in perinatal lethality (Cui et al. 2004).  
Because Stat5N mice are viable and combine the defects seen in null Stat5a and null 
Stat5b mice, they provide a model in which to study Stat5-mediated GH action.    
Similar to previous studies, we show that saline-treated Stat5N mice grew at a 
slower rate and had lower hepatic IGF-I expression and plasma IGF-I than WT mice 
(Teglund et al. 1998; Engblom et al. 2007).  IGF-I expression in muscle and adipose 
tissue of Stat5N also was reduced.  GH is known to stimulate hepatic IGF-I 
transcription via Stat5 (Woelfle & Rotwein 2004).  More significantly, we show that 
the impairment in growth is predominantly due to a lack of GH responsiveness.  GH 
treatment increased body weight gain in WT mice, but Stat5N mice completely failed 
to respond to GH.  Circulating IGF-I and hepatic IGF-I expression increased in GH-
treated WT mice while Stat5N mice were completely insensitive to GH.  Furthermore, 
GH stimulated IGF-I expression in WT mice while Stat5N mice fail to respond.   
Recently, Engblom et al. (2007) have shown that regulation of postnatal 
growth and hepatic IGF-I gene expression required an interaction between Stat5 and 
the glucocorticoid receptor (GR).  Chromatin immunoprecipitation (ChIP) assays 
demonstrate that the Stat5N protein is able to bind its cis-elements located in the GH-
regulated IGF-I and ALS genes.  The Stat5N protein, however, does not associate 
with the glucocorticoid receptor as wild type Stat5 does, suggesting that the N-
terminal domain of Stat5 serves as a docking platform for GR (Engblom et al. 2007).  
Our results suggest that the Stat5-GR interaction is important for GH-mediated IGF-I 
transcription not only in liver but also in muscle and adipose tissue.  This could be 
tested by performing ChIP assays in muscle and adipose of WT and Stat5N.   
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Chronic elevation of GH leads to insulin resistance (Dominici et al. 1999b).  
We show that a functional Stat5 protein is required for GH-induced insulin resistance. 
Recent studies have identified a molecular mechanism whereby GH antagonizes 
insulin signaling.  In muscle, GH-induction of the p85 subunit of PI3K reduces PI3K 
activity, resulting in insulin resistance (Barbour et al. 2005).  GH stimulated p85 
expression in WT but not in Stat5N mice.  These results suggest that GH-activated 
Stat5 binds to the p85 promoter and stimulates expression.  Promoter analysis of 
p85 could be used to test whether Stat5 mediates GH-stimulated p85 expression.  
This work would involve cloning of the p85 promoter and creation of a reporter 
construct driven by this promoter.  First, we would verify that GH induces p85 
expression in vitro.  The reporter construct could then be used in cell culture studies to 
determine whether GH activates the p85 promoter and whether it does so via Stat5 
binding to specific cis-elements. 
 The second experimental chapter of this dissertation focused on the role of the 
GH-IGF-I system in mammary development.  As reviewed in Chapter 2, ALS recruits 
liver-derived IGF-I in ternary complexes and in doing so, allows the development of 
the endocrine IGF-I system.  Characterization of null ALS mice demonstrated that 
ALS and IGF-I are needed for normal growth (Ueki et al. 2000).  Mammary gland 
development is also highly dependent on the GH-IGF-I system (Kleinberg & Ruan 
2008).  Thus, our second objective was to assess the role of ALS in mammary gland 
development.  In this survey, we found three specific defects in null ALS mice; 
delayed ductal elongation, impaired ductal branching and alveolar budding in early 
pregnancy, and delayed involution.  In addition, we detected significant ALS 
expression in the mammary gland at all stages examined, making it difficult to 
attribute exclusively any of these defects to disruption of the circulating IGF-I system.   
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 An additional complication is that the mammary gland is a heterogeneous 
tissue composed of epithelia, adipocytes, and connective tissue (Richert et al. 2000).  
The proportion of these compartments varies significantly throughout the different 
developmental stages.  We attempted to localize ALS protein in the mammary gland 
by immunohistochemistry in the virgin state, pregnancy, lactation, and involution.  
During all the developmental stages, ALS was present in the lumen of the ducts and/or 
alveoli, but we were unable to detect ALS within epithelial cells or adipocytes.  
Clearly, in situ hybridization studies will be necessary to identify the cell compartment 
expressing ALS during each phase of mammary development.  In the virgin state and 
during early pregnancy, the gland is composed predominantly of adipose tissue 
(Silberstein 2001), and we previously have shown that ALS is expressed in other 
adipose tissue depots (Giesy 2004).  In late pregnancy and throughout lactation, 
however, epithelial cells replace most of the adipocytes (Richert et al. 2000).  
Therefore, we speculate that mammary adipose tissue is likely the major site of ALS 
expression in pubertal development and early pregnancy, whereas epithelial cell 
expression predominates in late pregnancy, lactation, and involution.   
 Mammary ductal elongation is dependent upon estrogen, GH, and IGF-I.  Ruan 
et al. (1992) demonstrated that IGF-I can substitute for GH mediated mammary gland 
development in hypophysectomized rats.  Estrogen also plays a role in ductal 
elongation.  In mice lacking estrogen receptor  (ER), no ductal development occurs 
(Mallepell et al. 2006).  Moreover, estrogen enhances GH-induced expression of IGF-
I mRNA in the mammary fat pad and synergizes with IGF-I to stimulate ductal growth 
(Ruan et al. 1995).  The delay in ductal elongation is likely an IGF-I effect as plasma 
estradiol levels were adequate in null ALS mice.   
  IGF-I is also important in early pregnancy, promoting proliferation of ductal 
branches and formation of alveolar buds (Richert et al. 2000).  Mice lacking one copy 
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of the IGF-I gene have a systemic decrease in IGF-I expression, including the 
mammary gland and reduced circulating IGF-I levels.  During early pregnancy, these 
mice have impaired alveolar budding (Loladze et al. 2006), similar to what we observe 
in null ALS mice.  Presumably, mammary expression of IGF-I is normal in null ALS 
mice, leaving a plasma IGF-I deficit as the common feature between these models.     
 Perhaps the most interesting result with respect to mammary development was 
the delayed involution seen in null ALS mice.  This defect is more likely to relate to 
local rather than systemic ALS effects.  IGF-I promotes epithelial cell survival in WT 
mice (Green & Streuli 2004).  So, if systemic IGF-I did play a role in involution, then 
one would expect that the low levels of circulating IGF-I in null ALS mice would in 
fact accelerate the involution process.  Second, ALS is known to also form ternary 
complexes by interacting with IGF:IGFBP-5 complexes, perhaps providing a more 
effective mechanism to neutralize IGF-I.  The process of involution is irreversible 
after two days without milk removal (Richert et al. 2000).  Lactation can be re-
established in models having delayed involution, such as null Stat3 mice (Humphreys 
et al. 2002).  Given the slower rate of involution in null ALS mice, it would be 
interesting to determine if lactation could be resumed 4 or 6 days after pup removal.  
This would involve allowing WT and null ALS dams to nurse pups for 10 days, 
transferring their pups onto foster dams, and then after 4 or 6 days, transferring the 
pups back to their dams.   
 Clearly, we need to establish the spatial and temporal pattern of ALS 
expression in the mammary gland during development.  The other issue to address is 
whether ALS is affecting mammary gland development via alterations in the 
circulating IGF-I system or via local mechanisms.  This can be approached by ablating 
ALS expression specifically in liver.  We anticipate that such a model would 
recapitulate the low plasma IGF-I seen in null ALS mice.  Any mammary defect 
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remaining in a liver-specific null ALS model would implicate systemic ALS effects, 
such as the plasma IGF-I deficiency, rather than mammary ALS.  Another approach 
would be to eliminate ALS specifically in the mammary gland.  However, targeted 
deletion in the mammary gland is difficult, especially during pubertal development, 
early pregnancy, and involution when the tissue is a heterogeneous composite of 
adipocytes and epithelial cells.  Thus, studying mammary development in a liver-
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